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Abstract 
 
Antibiotic resistant bacteria have become a serious threat to modern 
medicine, as bacteria evolve new ways to counter existing treatments. 
Fluoroquinolones are an area of great interest for modifications and have 
been used as a framework for a range of conjugates, however 
fluoroquinolones can induce phototoxic effects in the patient by the 
generation of reactive oxygen species (ROS). Phenyl thiourea moieties are 
known to react with these ROS, thereby alleviating their toxic effect. In 
this work, the conjugation of ciprofloxacin a selection of substituted 
phenyl thioureas was investigated with the aim to of determining whether 
such conjugates could be viable as novel antibiotics whilst protecting 
against the phototoxic effects of fluoroquinolones. Four of these 
conjugates were successfully synthesised and screened against the 
BW25113 strain of E. coli. However, the conjugates were observed to have 
a higher MIC, i.e. lower antimicrobial activity, than ciprofloxacin. To probe 
if the drop in antimicrobial activity correlates with a decrease in the 
affinity of the conjugate for the drug target, DNA gyrase, a DNA gyrase 
binding assay was carried out. It was observed that the binding affinity of 
the conjugate had decreased.  It was therefore concluded that the 
attachment of a thiourea moiety to ciprofloxacin decreases the DNA 
gyrase inhibitory activity of the parent drug, ciprofloxacin. 
 
As an extension a study was undertaken into the use of a biolabile 
disulfide linker between the two moieties to investigate whether it would 
be suitable as a delivery mechanism for a ciprofloxacin thiourea 
conjugate. The initial synthetic target was a dimer of ciprofloxacin linked 
with a disulfide bridge, to allow the assessment of the disulfide. Screening 
of this molecule showed that the disulfide link was increasing the MIC 
compared to the monomer of ciprofloxacin. 
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1.0 Introduction 
 
1.1 Antibiotics 
 
The term “antibiotic” was coined in 1941 to mean a class of molecules 
that kills or inhibits bacterial growth.1 The discovery of penicillins 1 (1929), 
streptomycin 2 (1943), tetracycline 3 (1944) and chloramphenicol 4 
(1946)2 provided the starting point for the Golden Age of Antibiotics from 
1950-1960. During the 1950s, around 50% of modern antibiotics used 
today were developed. 3 
 
 
 
Despite the initial successes, in the last fifty years only two new classes of 
synthetic antibiotics have been developed. These were the quinolones in 
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1962 and oxazolidinones in 2000, examples of which include ciprofloxacin 
5 and linezolid 6.2 The lack of investment into new antibiotics, combined 
with overuse  has led to the appearance of new multi-drug resistant 
(MDR) strains of pathogens.4 
 
 
 
1.1.1 Antibiotic Resistance 
Antibiotic resistance is now a threat to modern medicine. Not only are 
infections becoming harder to treat but routine operations are at risk of 
untreatable infection. In September of 2016, speaking at a UN general 
assembly, the Secretary General Ban Ki-moon called it a “fundamental, 
long-term threat to human health, sustainable food production and 
development.” 5 
 
Antibiotic resistance can arise through different mechanisms: modification 
of target site, enzymatic deactivation, active efflux, a change in metabolic 
pathways or a decreased permeability at the cell membrane.4 Once 
resistance has arisen, it will spread rapidly throughout a population 
vertically, through natural selection, and horizontally through plasmid 
transfer.1 These are shown in Figure 1. 
16 
 
 
 
Figure 1 Schematic showing differing mechanisms of bacterial antibiotic resistance 6 
 
1.1.2 Intracellular Target Site Modification 
To function as an antibiotic, the molecule must be able to bind to a 
specific target within the bacterial cell, therefore they are highly affected 
by a change in their target binding site. For example, the growing cell wall 
of Gram-positive bacteria is dependent on the extension of peptidoglycan 
chains. Without them, the bacterium can no longer contain its inner 
osmotic pressure and will rupture its cell membrane.7 Vancomycin, 7, 
inhibits the extension of these chains by hydrogen bonding to the growing 
tip and capping it as shown in Figure 2. In the case of the Vancomycin-
resistant strains of E. faecium, two gene clusters, VanA and VanB, have 
been identified to encode enzymes that alter the peptidoglycan 
Active efflux 
Reduced membrane 
permeability 
Enzymatic degradation of 
antibiotic 
Alteration of target site 
Altered cellular metabolism 
Antibiotic molecule Protein transporter 
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precursors from D-Ala-D-Ala to D-Ala-D Lac. This change of terminal amino 
acid residue to lactate severely inhibits Vancomycin binding.8 The change 
in structure changes the bonding pattern from five hydrogen bonds to 
four which results in a thousand-fold decrease in binding affinity.9 
 
 
Figure 2 Vancomycin binding interactions with a growing peptidoglycan chain 10 
 
1.1.3 Antibiotic deactivation 
When challenged with an antibiotic, bacteria can evolve enzymes that 
deactivate an antibiotic via covalent modification. An example of chemical 
modification is the degradation of β-lactam antibiotics by the β-
lactamases. This enzyme hydrolyses the essential ring structure in β-
lactam antibiotics, converting the drug to an inactive form as shown in 
Scheme 1. These enzymes were initially discovered in 1940,11 one year 
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before the first clinical use of penicillins. Since then this family of enzymes 
has had over 1,300 distinct members identified.12 
 
 
Scheme 1 The effect of β-lactamases on amoxicillin 13 
 
The β-lactamase class of enzymes binds and open the β-lactam four 
membered ring. During its action the penicillin binds to a target, a 
member of the penicillin binding protein (PBP) family and irreversibly 
acylates it. 13 The β-lactam ring is essential for this process. A β-lactamase 
will react with, and open this ring in such a way that the β-lactamase can 
be recycled. 13 
 
1.1.4 Antibiotic efflux 
There are many bacterial membrane-bound efflux pumps. Normally these 
proteins are responsible for removing toxic compounds. For example, the 
E.coli AcrAB efflux system normally removes excess fatty and bile acids, 
however it has also been found to be the major pumping system 
responsible for resistance to tetracyclines, penicillins and 
fluoroquinolones in E. coli.14 Due to this broad spectrum of activity, one 
efflux system can result in resistance to a wide variety of antibiotics.15 The  
upregulation or development of a new transporter that can effectively 
transport the antibiotic away from its target site leads to the bacterium 
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becoming resistant.6,15 Coldham et al. report that fluoroquinolone 
exposure increases the expression of 43 separate proteins in E. coli, 
including the AcrAB family of pumps. There is a great deal of research 
investigating whether chemical modifications can inhibit this efflux. 
 
1.1.5 Altered Cellular Metabolism 
The overexpression of targets can result in resistance to an antibiotic. The 
more of a target there is present in the cell, the higher the local 
concentration of antibiotic that is necessary to disrupt its function. For 
example incubation with low levels of Vancomycin will result in bacteria 
developing a much thicker cell wall, to increase the number of 
peptidoglycan chains and hence the number of targets.6 
 
1.1.6 Reduced Cell Permeability of Antibiotics 
Due to the hydrophobic nature of the inner cell membrane, many polar 
antibiotics find it difficult to penetrate the bacterial cell by diffusion 
alone.16 The outer membrane of Gram-negative bacteria also contains a 
high proportion of lipopolysaccharides. These are highly anionic and 
coordinate divalent Mg2+ and Ca2+ cations from the surrounding 
environment. This network of charged ions provides a significant barrier 
to hydrophobic or detergent-like antibiotics such as the 
fluoroquinolones.17  Fluoroquinolones are known to bind to Mg2+ ions and 
can be held in place at the membrane.18 Instead of diffusion, a large 
proportion of antibiotics use porins to gain access to the intracellular 
target.16 Porins are large, hollow β-barrel structured proteins that sit in 
the bacterial membranes and allow ions and small molecules to diffuse 
across.19 OmpF is a major porin involved in fluoroquinolone uptake.20 As 
such, the bacteria can gain at least partial resistance to an antibiotic by 
downregulating or otherwise modifying these uptake pathways.21 It is 
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possible that modifications that remove the zwitterionic nature of 
ciprofloxacin and make it more lipophilic would increase the rate of 
passive diffusion through the bacterial cell membrane. 
 
1.1.7 Preventing Antibiotic Resistance 
The fight to stop bacteria evolving resistance to antibiotics has always 
been a losing fight.3 The arms race between microorganisms developing 
new ways of attack and defence is driven by natural selection.22 However 
there are several ways that humankind can reduce the rate of resistance 
development: reducing the over prescription of antibiotics and the 
prescription for minor illnesses, reducing the use of antibiotics in livestock 
and agriculture and ensuring the proper disposal of antibiotics to prevent 
contamination of groundwater.3 As well as this it is important that new 
antibiotics are developed in response to new resistance that arises. These 
can be new modifications of existing antibiotics or even entirely new 
antibiotics designed for newly discovered intracellular targets.6 
 
1.1.8 Combination Therapy 
To overcome resistance, many antibiotics are used together with another 
molecule aimed to protect it, or to act synergistically at either the same 
target site or another in the bacterium.23 The aim is to completely wipe 
out a population of bacteria so that there are no survivors to develop 
resistance. The principle was first demonstrated with β-lactamase 
inhibitors prescribed in conjunction with β-lactam antibiotics. Amoxicillin, 
8, and clavulanic acid, 9, was the first therapeutically used combination, 
first employed in 1981.23 Clavulanic acid is a β-lactamase inhibitor and 
prevents the hydrolysis of amoxicillin by these enzymes. The addition of 
clavulanic acid was found to greatly increase the susceptibility of β-
lactamase producing pathogens to amoxicillin.23 
21 
 
 
 
 
From this first combination therapy, more clinical examples have been 
developed, including examples involving the fluoroquinolones. A 
combination therapy containing the antibiotic ciprofloxacin, 6, and 
probenecid, 10, an inhibitor of the renal organic anion transport system. 
Inhibiting these transport systems slows the rate of renal excretion of 
ciprofloxacin.24 This has been shown to increase the plasma concentration 
and biological half-life of ciprofloxacin, increasing its efficacy.25 
 
 
 
The recognition of the importance of combination therapy and the 
opportunities it presents has led to the creation of the field of 
perturbation biology. This involves the prediction of how cells will act 
once ‘perturbed’ by an outside action and uses computational modelling 
of cellular metabolic pathways pioneered by Molinelli et al. in 2013. 
Initially developed for studying cancer cells, it has been expanded to 
22 
 
model the impact of antibiotics, including fluoroquinolones such as 
ciprofloxacin, on gut flora. 26 
 
1.2 Fluoroquinolones 
 
Fluoroquinolones are an essential part of the arsenal of modern medicine. 
Initially targeted against Gram-negative urinary tract infections, later 
generations can also target Gram-positive bacteria. However, resistance is 
rising. In 2009, in British Columbia, more than 20% of E. coli and K. 
pneumoniae infections were found to be resistant to fluoroquinolones. 
This is up from around 2% of resistant cases found in 1996.27  
 
1.2.1 Development of the Fluoroquinolone Class of Antibiotic 
The first precursor of this class of antibiotics was nalidixic acid, 11. This is 
regarded as the first generation of quinolones.28 It was first introduced in 
1962 as an agent against Gram-negative bacterial infections of the urinary 
tract.24 However nalidixic acid only acted on a very narrow spectrum of 
bacteria which led to the development of the second generation, the 
fluoroquinolones. These can be further classified into Class 1 and Class 2. 
Class 1 fluoroquinolones, for example norfloxacin, 12,  had an improved 
Gram-negative coverage and a small spectrum of Gram-positive activity.24 
Class 2 fluoroquinolones such as ciprofloxacin 6 had a wider bioavailability 
and were used to treat a wider variety of infections.28 
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Further development of the third and fourth generations of 
fluoroquinolones widened the spectrum of susceptible bacteria.28 The 
third generation, such as moxifloxacin 13, were developed and found to 
have modest streptococcal coverage.24 The fourth generation, such as 
trovafloxacin 14, in particular was found to have action on Methicillin-
resistant Staphylococcus aureus (MRSA)24 
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1.2.2 Fluoroquinolone Toxicity 
Fluoroquinolones as a class are generally considered to be mild 
antibiotics. Most adverse side effects are gastrointestinal upset (>7%) with 
very rare cases of central nervous system events (>5%), blood disorders 
(approximately 5%), renal disturbances (approximately 4.5%) and skin 
photosensitivity (approximately 2%).29 
 
Fluoroquinolones are known for their photosensitising properties causing 
phototoxicity in human and animal models.30 Both photoallergic reactions, 
an immune response based on previous exposure to fluoroquinolone 
antibiotics, and phototoxic responses have been documented.29 Once 
excited by ultraviolet light, fluoroquinolones generate ROS. These include 
the singlet oxygen species 1O2 which then decomposes to hydrogen 
peroxide, H2O2. These ROS can attack lipid membranes and cause DNA 
damage.29 This lead to the development of tumours in mice treated with 
lomefloxacin.29 M. Peacock et al. also report that the nucleotide excision 
repair (NER) pathway of DNA repair was heavily damaged by these ROS, 
increasing the chances of cells becoming cancerous.31  Increased toxicity is 
linked with the C-8 halogenated position in fluoroquinolones.30 There is 
scope for conjugates therapies that will counteract this toxicity by reacting 
with and removing the ROS. However, this would have to be balanced 
against the reduced potency of the fluoroquinolones. 
 
Hayashi et al. report that modifications at position 1 of 7-(3-
aminopyrrolidinyl) quinolones such as an aminodifluorophenyl, 15, or an 
isoxazolyl group, 16, decrease the phototoxicity. However, these 
modifications also resulted in a decrease in antibacterial activity. There is 
potential for modifications elsewhere on the fluoroquinolone could have  
similar effect without the loss of efficacy, and indeed this is what lead to 
the design of the thiourea conjugation on to the piperazine.32 
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1.2.3 Fluoroquinolone Structure-Function  
Since the initial discovery of nalidixic acid, there has been extensive 
research into how modifications on the bicyclic structure, 17, affects the 
activity. 
 
 
Figure 3 The pharmacophore of the fluoroquinolone class of antibiotics 
 
The potency of the pharmacophore is increased by a cyclopropyl group at 
N1, exemplified by ciprofloxacin and found in third and fourth generations 
of fluoroquinolones.33 One of the earliest additions to the quinolone 
pharmacophore was the fluorine at position 7. With this addition there 
was a 10-fold increase in DNA gyrase inhibition.33 Attaching a five or six 
membered nitrogen heterocycle at the C8 position influences the 
pharmacokinetics of the antibiotics.34 A piperazine will increase activity 
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against Gram-negative bacteria. An amino pyrrolidine group extends the 
spectrum of activity to Gram-positive bacteria.34 It is thought that these 
groups inhibit efflux and so improve potency.33 
 
The carboxylic acid at position C3 and the carbonyl at C4 are known to be 
essential for the formation of the bound gyrase complex.35 These groups 
are involved in the formation of the Mg2+ water bridge for tight complex 
binding. If these groups are chemically modified or removed, the activity is 
reduced.36 This factor was a major influence in the decision to conjugate 
the phenyl thiourea to the piperazine as discussed in later chapters.  
 
1.2.4 Fluoroquinolone Uptake 
Ciprofloxacin has two protonation sites. In water, the carboxylic acid has a 
pKa of 6.5 and the terminal nitrogen on the piperazine has a  pKaH of 7.5.17 
Fluoroquinolones are also known to coordinate Mg2+ ions, which confers a 
positive charge to the complex. Once the molecule is charged, it is 
excluded from the lipid bilayer,18 however it is known that porins in the 
bacterial outer membrane have a preference for transporting cations.37 
The porin OmpF is widely acknowledged as the primary fluoroquinolone 
transporter in the E. coli bacterial membrane.16–18,37 As the modifications 
would mask the ionisable groups, it was theorised that they would 
improve the rate of diffusion across the bacterial plasma membrane.  
 
1.2.5 DNA Gyrase and Topoisomerase IV 
DNA gyrase is an enzyme responsible for the supercoiling of bacterial DNA 
in an series of reactions involving adenylate triphosphate (ATP) 
hydrolysis.38 Gyrase is classed a Type II Topoisomerase, as it catalyses the 
breaking and reforming of both strands of DNA. The enzyme passes the 
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cut sections of duplex DNA through each other to remove or induce 
supercoils and knots as shown in Figure 4. It is active primarily during DNA 
replication to remove topological tension in the double helix caused by 
the replisome unwinding the double strands. Other roles include the 
folding and coiling of the bacterial chromosome, the knotting of plasmids 
and protecting the DNA from high temperatures.35 DNA Gyrase binds as a 
tetramer around DNA as a dimer of dimers, containing two of each 
subunits denoted as GyrA and GyrB.35 In the presence of ATP, DNA Gyrase 
introduces negative supercoiling into DNA. In the absence of ATP, DNA 
Gyrase removes supercoils. In this way, it is sensitive to the currently 
energy levels of the cell, which is in turn affected by the extracellular 
environment.35 
 
 
Figure 4 Sequential steps of DNA Gyrase passing one strand of DNA through another, 
using ATP. Figure numbering corresponds to the order of the steps in the cycle. Figure 
used with permission.39 
 
Topoisomerase IV is another Type II topoisomerase. It is responsible for 
decatenating replicated circular DNA, as the semi-conservative method of 
DNA replication leaves the strands intertwined.35 There is also evidence 
for it being involved in anchoring the newly replicated DNA to the 
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membrane, to aid in separation in much the same way spindle fibres do in 
eukaryotic cells.40  
 
1.2.6 Fluoroquinolones Binding to DNA Gyrase 
Fluoroquinolone antibiotics bind to DNA gyrase in the midst of the 
catalytic cycle, when the duplex DNA has been cut.35 The stoichiometry is 
two fluoroquinolones per tetrad of gyrase subunit. Antibiotic binding in 
this way is DNA dependent and the molecules have a low affinity for free 
gyrase.41 Gyrase itself forms a binding pocket for the fluoroquinolone in 
relaxed DNA substrate in the presence of ATP.42 The drug intercalates into 
nicks in the DNA created by the enzyme.43 The binding complex involves 
the carboxylic acids and carbonyl of the quinolone form a Mg2+ - water 
bridge to an aspartic/glutamic acid residue and a serine in helix IV of a 
GyrA subunit, as seen in Figure 5.43 In E. coli the residues are Ser366 and 
Asp370 of GyrA and these are the residues most commonly associated 
with target-site modification resistance.44,45 
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Figure 5 Ciprofloxacin – Mg2+ - water – enzyme bridge binding interactions adapted 
from Mustaev et al. 43 The dashed lines indicate hydrogen bonds 
 
There is also substantial evidence for a second binding mode, however 
this has yet to be fully elucidated. It has been observed that the C-7 ring of 
fluoroquinolones interact with both GyrA and GyrB subunits. When point 
cysteine mutations were introduced and a modified chloroacetyl 
derivative of Ciprofloxacin bound, there was an unexpected cross link 
formation, correlated with exceptional bacteriostatic activity. The residues 
in question, GyrA-Gly81 and GyrB-Glu466 are around 17 Å apart, which 
suggests there are two separate binding interactions occurring.43 These 
binding modes indicate that the pharmacophore is integral to the binding 
complex, and modifying these groups is likely to adversely affect the 
efficacy of any conjugate.  
 
1.2.7 Protein Synthesis Dependent and Independent Modes of Action 
Fluoroquinolones have two bactericidal mechanisms of action, one is 
protein synthesis dependent and the other is protein synthesis 
independent. These situations relate to whether or not a bacterium is 
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currently growing and reproducing.46 This classification arises from the 
observation that the action of nalidixic acid being blocked by inhibiting 
protein synthesis with a prior incubation with chloramphenicol, however 
the action of ciprofloxacin is left unaffected.46 Both of these processes 
follow on from the formation of double stranded DNA breaks capped with 
protein.46 Both processes result in chromosome fragmentation, however 
even a single DNA double strand break can be lethal.47 Previously it was 
thought that lethal DNA breaks occurred when the replication fork 
collided with the Gyrase-DNA complex, however recent evidence has 
shown that this is not the case.46 The ‘capping’ of the broken DNA with 
Gyrase allows the DNA to reform intact. Therefore in order to be lethal, 
the complex must dissociate and the fragments be released.46 
 
Fluoroquinolone lethality has also been found to involve reactive oxygen 
species (ROS).48 It has been observed that a hydroxyl radical scavenger will 
completely inhibit the activity of oxolinic acid, 18, but only partially inhibit 
moxifloxacin, 13.48 In fact, the same amount of inhibition occurs with both 
a pre-incubation of chloramphenicol as with a radical scavenger, and used 
together causes no additional effect. It can therefore be concluded that 
the protein synthesis dependent pathway depends upon these hydroxyl 
radicals, and that the protein synthesis independent pathway does not.  
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The normal route of reactive oxygen species is shown in Scheme 2. It has 
been found that a double deficiency in the sodA and sodB superoxide 
dismutase enzymes in E. coli will decrease the lethality of norfloxacin, 
whereas a single knockout mutation in either one has no effect.49 Further 
studies showed that a knockout mutation of catalase enzymes will 
drastically increase the lethality of norfloxacin. An iron chelator and a 
hydroxyl radical scavenging thiourea both reduced the activity of 
norfloxacin. The same experiments had no effect on the activity of 
chloramphenicol. Taken together, these findings suggest that the 
norfloxacin was generating the superoxide species, that was then 
converted to damaging hydroxyl radicals via hydrogen peroxide.49 
 
 
Scheme 2 Superoxide decomposition pathways48 
 
Other studies performed on Mycobacteria proteasome accessory factor C 
(pafC) have found similar results. PafC is a factor in how mycobacteria 
break down proteins using superoxide species up in the process.50 
Knockout mutations were found to potentiate hypersensitivity to 
fluoroquinolones but no other classes of antibiotic. Exposure to thiourea 
or iron chelators was found to remove this hypersensitivity.50 This 
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evidence points to the importance of reactive oxygen species in 
fluoroquinolone lethality.  
 
The thiourea group was chosen as a conjugate to try and limit the 
damaging effect of ROS, which account for the phototoxicity of the 
fluoroquinolones. 
 
1.2.8 Resistance to Fluoroquinolones  
Specific target alteration of the DNA Gyrase GyrA subunit and 
Topoisomerase IV ParC subunit is a common mechanism of resistance, 
and possibly the most clinically important one.51 The mutation most 
notably involved in E. coIi Gyrase target modification is Ser82.21 Other 
mutations are usually found amongst residues 67-106 in what is known as 
the quinolone resistance determining region (QRDR)52 This region is the 
binding pocket for DNA Gyrase onto DNA and as fluoroquinolones bind on 
to the DNA Gyrase-DNA complex any alterations here can reduce the 
binding affinity.51 Overcoming this kind of resistance is extremely difficult 
and no such examples have reached clinical use.21 
 
Other chromosome-based methods of resistance exist. Fluoroquinolones 
cross the bacterial membrane mainly making use of porins, though they 
can diffuse across.17 It has been shown that quinolone activity can 
decrease the synthesis of OmpF, one of two major porins in E. coli.53 
Under ideal growth conditions, this can lead to increased fluoroquinolone 
resistance, however due to the porin being an important ion channel too, 
taking steps to abolish the proton motive force will result in it being 
synthesised again.53 Therefore, this is not an absolute mechanism 
resistance for bacteria and other mechanisms must exist. Since the design 
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of the conjugates was aimed to increase lipophilicity it was theorised that 
the OmpF porin uptake pathway could be circumvented.  
 
Three main types of plasmid-based resistance occur. Qnr proteins are part 
of a family of pentapeptide repeat proteins and share homology with DNA 
mimics. These bind to DNA Gyrase and topoisomerase IV both in the 
cytoplasm and while complexed to DNA to reduce the number of enzyme 
target sites for fluoroquinolones and hence their efficacy.21,54 The second 
type is an aac(6′)-Ib-cr mutant protein belonging to the aminoglycoside 
transferase family. The enzyme acetylates the piperazine ring found in 
Ciprofloxacin and Norfloxacin, reducing the activity.21 The third is a family 
of Multidrug Resistance (MDR) transporters which are a classification of 
membrane based efflux proteins.53 A significant mechanism of resistance 
is the evolution and overexpression of these transports.55 Three members 
have been identified to be involved in fluoroquinolone resistance, OqxAB, 
QepA1, and QepA2.21  
 
1.2.9 Fluoroquinolone Conjugate Therapies 
The development of the different generations of fluoroquinolones has 
shown that they are an excellent target for further modifications. Having 
two intracellular targets can be beneficial, especially if a modification 
decreasing binding affinity at one could be offset by increased inhibition 
of the other.56  
 
As discussed above, the C-3 carboxyl and the C4 carbonyl are essential for 
fluoroquinolone function. As a result, non-immolative attachments at this 
point can have a detrimental effect on the efficacy. Replacing the 
carboxylic acid with a hydrazide, 19, decreases the zone of inhibition (ZI) 
when tested against S. aureus in well-diffusion assays.57 
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Due to the downsides mentioned above, extensive work has been carried 
out investigating the effects of modifying the piperazine ring of 
ciprofloxacin. In 2012 S. Wang et al. found that modifying ciprofloxacin 
with a N-terminal 4-methoxybenzene, 20, was up to eight times more 
potent than ciprofloxacin against Gram-positive bacteria.58 Their 
reasoning being that, in general, fluoroquinolone activity increases with 
lipophilicity.59 
 
 
 
This is very much an area of active research. Leading on from simple 
chemical modifications, investigations into linking two antibiotic moieties 
together were performed. In 2016 S. Panda et al. published a study on a 
conjugate between fluoroquinolones and the antituberculotic drug 
pyrazinamide. Pyrazinamide derivatives have been shown to have 
increased effect on drug resistant tuberculosis. The ciprofloxacin-alanine-
pyrazinamide conjugate, 21, had a drastically reduced MIC against S. 
aureus but an increased MIC against S. typhi.  
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 Some of the most successful hybrid antimicrobials involve the 
conjugation of fluoroquinolones to oxazolidinones, 22.56 Oxazolidinones 
inhibit protein synthesis by binding the P-site of the ribosomal protein 
synthesis complex.60 It has been reported that conjugates with structures 
based on this have shown to have a lower MIC than Moxifloxacin and 
activity against several MDR strains of pathogens.56 
 
 
Figure 6 General structure of fluoroquinolone-oxazolidinone conjugate hybrids. R = cPr, 
Et, X = N, CH, Y = CF, N, Z =NHAc, NH(CS)OMe56 
 
Another example is the rifampin-fluoroquinolone conjugate, 23. This is 
rifampicin conjugated to a fluoroquinolone via a hydrazide. Rifampicin is a 
potent inhibitor of bacterial RNA polymerase in a wide variety of Gram-
positive bacteria, however resistance quickly and easily arise via point 
mutations. Combining it with fluoroquinolones helped prevent this 
resistance arising as it was discovered at affect three separate targets, 
RNA polymerase, DNA gyrase and topoisomerase IV.56 
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Some of the most recent conjugate therapies are antibiotic-antibody 
conjugates (AACs). These AACs are combine the target site specificity, 
superior absorbance and distribution of antibiotics with the favourable 
pharmacokinetics of antibodies, namely long half-life and slow 
clearance.61 The conjugate system binds to the antigens via the antibody 
section and the bound AAC-bacterium is recognised by the immune 
system of the host and taken up. Inside the cell the bacterium is 
destroyed, in part by the immune cell and in part by the conjugated 
antibiotic.61 While still a very novel area of research, fluoroquinolone 
based AACs could hold great potential. 
 
1.2.10 Fluoroquinolone Dimers 
Fluoroquinolone dimers have been a topic of in depth research, as the 
structure of the gyrase binding site and the stoichiometry of binding have 
led to the possibility of bisintercalation into the two binding sites.62 
Previous examples have used permanent linkers between the two 
fluoroquinolone moieties. In 2006 Kerns et al. developed the 
fluoroquinolone dimers, 24. These dimers were found to be equipotent or 
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±2-fold MIC against ciprofloxacin susceptible strains of S. pneumoniae. 
However, the dimers had reduced MIC compared to ciprofloxacin when 
tested on ciprofloxacin resistant strains of S. pneumoniae possessing 
efflux-mediated or topoisomerase IV mutation-mediated resistance 
mechanisms. However they were also found to have a raised MIC against 
Gram-negative bacteria.63 
 
 
Figure 7 Ciprofloxacin dimers synthesised with a range of linkers, adapted from Kerns 
et al.63 
 
In 2015, A. Ross et al. undertook further analysis of ciprofloxacin dimers. 
Amide linked dimers, 25 and 26,  were synthesised with the aim of 
improving interactions with DNA and the solubility profile.62 However the 
dimerisation resulted in a drastically increased MIC (32 µM) against E. coli 
compared to ciprofloxacin (<0.03 µM). The MIC was decreased when 
tested against an imp-4213 outer membrane permeability mutant, 
suggesting that part of the problem was with diffusion past the 
membrane, however direct DNA Gyrase assays indicated a three-fold 
decrease in IC50, leading them to conclude that it was a combination of 
these two effects.62 
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Ross et al. also investigated PEG dimers of ciprofloxacin. The most 
efficacious one of these, 27, had a much lower MIC than the amide linked 
dimers, however still much higher than ciprofloxacin. Interestingly, the 
IC50 of DNA Gyrase was much higher for 27 than 25 and 26, and the MIC 
for the imp-4213 mutant was lower for 27. This suggest that the 
PEGylation is reducing Gyrase binding but increasing the membrane 
permeability of 27.62 It is hypothesised that the PEG linker can stretch 
across the phospholipid bilayer without concomitant membrane 
disruption.62 It was thought that this could also apply to the disulfide link 
based dimer investigated in the later chapters. 
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These results indicate that the correct linker design can improve upon the 
rate of cellular uptake for the antibiotic to offset the decrease binding 
affinity for DNA Gyrase. This led to us considering the effect of biolabile 
linkers eliminate the problems of permanent linkers while retaining the 
benefits.  
 
1.3 Biolabile Linkers 
 
All the above examples use a permanent linker between the two drug 
moieties. It has been observed that permanently modifying 
fluoroquinolones can decrease their efficacy in vitro.33,36,64–66 Co-drugs can 
be designed with a biolabile linker and are known as mutual prodrugs, as 
they act as a mutual pro-moiety for each other.67 The criteria for a mutual 
prodrug are (a) the prodrug itself is not pharmacologically active, (b) the 
release of the two drugs is fast and does not produce toxic side products, 
(c) the linker should be bio-cleavable by enzymes or other cellular 
agents.67 
 
In 2014, Sinha, S et al. filed a patent for a variety of covalently linked 
conjugates, for example the gatifloxacin-prednisolone conjugate, 28.68 
Prednisolone, as a corticosteroid, is highly lipophilic so it was thought that 
conjugation could improve the ability of the drug to permeate lipid 
bilayers.69 Once inside the cell, the molecule is theorised to be hydrolysed 
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and the two drug moieties released, though whether this is an enzyme-
mediated process or not is unknown. Once released, the antibiotic 
gatifloxacin and the anti-inflammatory prednisolone would act 
independently from each other.  
 
 
 
1.3.1 Disulfide Bridges 
The dimer designed in this work would incorporate a biolabile link 
designed to break down in the bacterial cytoplasm, specifically a disulfide 
bridge between two ciprofloxacin molecules. The structure, 29, is the 
general structure for the disulfide bridge.  
 
 
 
The S-S connection is seen extensively in proteins where it assists in the 
folding of the protein.70 It is also commonly associated with cellular 
reducing agents, such as glutathione 30 or free cysteine.67,71 Glutathione 
acts as an antioxidant in the cell via conversion to the Glutathione 
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Disulfide, 31. It can be converted back to Glutathione by the NADP-H 
dependent enzyme Glutathione Reductase (Scheme 3).72 
 
 
Scheme 3 Interconversion of Glutathione and Glutathione Disulfide in a redox process 
 
1.3.2 Disulfide linker Reductive Cleavage 
Jain et al. synthesised several prodrugs and conducted mechanistic studies 
into how the disulfide bridge cleaves.67 They detected the by-products 
monothiolcarbonate, 32, ethylene sulphide, 33, and CO2, as well as the 
released terminal drug moieties shown in Scheme 4. It was proposed that 
the bridge cleaves due to cellular thiol groups on glutathione and cysteine 
residues. This would only release the drug once in the cytoplasm of the 
bacterial cell.  
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Scheme 4 Disulfide bridge breakdown in the presence of cellular reducing agents. 
Scheme adapted from Jain et al. 67 
 
1.3.3 Disulfide Linkers can be Tuned 
The structure of the disulfide can be ‘tuned’ to affect the rates of 
breakdown. Using luciferin as a releasable fluorophore, Jones et al. found 
that increasing the length of the carbon chain slowed the rate of Luciferin 
release, as the longer chained monothiol intermediate took longer to 
decompose extracellularly.73 However when incubated with a 1 mM 
concentration of the redox agent dithiothreitol (DTT) for thirty minutes it 
was seen that the disulfide decomposed fully for both examples, 35A and 
35B. From this Jones et al. concluded that intracellular release was still 
very quick, no matter the length of the chain. 
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Figure 8 Luciferin-disulfide-polypeptide conjugate with variable chain length. 33A n=2, 
33B n=3 
 
It has also been reported that sterically hindering the disulfide chain can 
decrease the rate of release.74 Initially, disulfides were considered to 
cleave in the extracellular medium and release the drug at non-target 
sites. However molecules with sterically-hindered linkers were found to 
have much larger half lives in vivo.75 Phillips et al. report that increasingly 
hindering the linker with methyl groups as shown by 36A-D gives 
increasing biological half-life and slower clearance in vivo in antibody 
conjugated molecules.76 This would allow further tuning of future 
ciprofloxacin conjugates made using the disulfide to increase its activity in 
vivo.  
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1.3.4 Disulfide Based Drug Uptake 
Whilst it is thought that small molecule-based conjugates can diffuse 
through the cell membrane, it is increasingly clear that there is an 
endocytotic mechanism of uptake for the larger polypeptide-drug and 
antibody-drug conjugates in eukaryotes.77 Once taken up in this manner, 
the disulfide linkage remains intact until the lysozyme is dissipated, as the 
interior is oxidising and acidic.77 There is also clear evidence that the 
disulfide can trigger the uptake of previously membrane-impermeable 
polypeptides via conjugation to an actively transported moiety.73  
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Evidence exists for a disulfide containing protein shuttling mechanism in 
the E. coli periplasm. The disulfide bond forming (Dsb) proteins are active 
in the periplasm to form disulfide bonds in the oxidising extracellular 
environment. It has been reported that DsbD can transport intact disulfide 
bonds across the cell membrane.78 
 
1.3.5 Disulfide Based Prodrugs 
The advantage of the disulfide bridge is that it is resistant to the oxidising 
environment of the extracellular fluid whilst being vulnerable to break 
down in the reducing environment of the cell. This property allows drugs 
to be very narrowly targeted, resulting in an increased local concentration 
at the target site.79 It also allows precise delivery of cytotoxic components, 
such as nitric oxide-diclofenac prodrugs, 37.80 Containing the breakdown 
to the cytoplasm avoids the highly toxic effects that diclofenac, 38, has on 
the gastrointestinal tract.81 
 
 
Scheme 5 Cleavage of the diclofenac-disulfide-NO2 conjugate 
  
Another use is as diagnostic probes for the redox state of cells, as 
indicated by the level of free reactive Glutathione. Molecular probes 
incorporating fluorescent naphthalimide, 39, have been developed using 
the disulfide bridge.82 Once the disulfide cleaves, the fluorescence of the 
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naphthalimide, 40, moiety changes, indicated an area of redox stress. This 
can help identify cancerous tissue.83 The fluorescence-changing would 
also allow investigations into the rate of cleavage of the ciprofloxacin 
dimers discussed in later chapters.  
 
 
Scheme 6 Cleavage of a naphthalimide based fluorescent probe 
 
Disulfide bridges have started to be used as linkers between antibodies 
and antibiotics.84 Small molecules can be conjugated to free cysteine 
residues on a mutant antibody to take advantage of the antibody’s 
superior biostability. Target cell internalisation and degradation of the 
antibody via lysozyme leads to release of the antibiotic inside.84 The 
disulfide linker is thought to break down inside the cytoplasm of the cell, 
having escaped the strongly oxidising environment of the lysozyme.85 
There were initially problems with this design. The linker would break 
down through thiol exchange leading to a very fast clearance of the 
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attached drug. More recently advances have been made to improve the 
stability of the linker with hindered disulfide linkers, however there is little 
data available on the longer term activity and half-life within in vivo 
models.86 
 
1.4 Thioureas 
 
 
Figure 9 General thiourea functional group 
 
Thioureas, 41, are known to have antimicrobial, antiviral and anticancer 
properties.87 Thioureas have a broad spectrum of antibacterial activity,88 
especially when conjugated to adjacent aromatic systems. Examples 
include thiacetazone 42, mathisazone, 43, and thiocarlide, 44, that are 
known to have antibiotic properties.89 
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1.4.1 Interactions with DNA Gyrase 
Phenyl thiourea based compounds containing a 3-trifluoromethylphenyl 
group have been shown to inhibit the action of DNA Gyrase and 
topoisomerase IV, similar to the fluoroquinolones.90 The most active of 
these compounds, 45, provided a starting point for the design of the 
library of thiourea conjugates chosen as synthetic targets.  
 
 
 
It was found that halogenated, especially fluorinated,  phenyl rings are the 
best substituents for the R group, a factor that influenced the choice of 
target molecules discussed in later chapters.90  
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Docking studies involving quinolones conjugated to thioureas have begun 
to elucidate how those compounds bind. In 2015 Medapi et al. performed 
docking studies on a series of quinolone-thiourea hybrids. They report 
multiple binding modes to the GyrB subunit of Mycobacterium 
tuberculosis, shown in Figure 10.91 These multiple binding modes are very 
dependent on the modifications made to the adjacent phenyl ring to the 
thiourea. This prompted the investigation into synthesising a library of 
halogenated phenyl thioureas, to determine whether this would affect the 
potency of the conjugates.  
 
 
Figure 10 The binding modes of three thiourea quinolone conjugates in GyrB subunit of 
DNA gyrase in Mycobacterium tuburculosis. The strongest binding mode (lowest IC50) if 
shown on the right.91 
 
1.4.2 Thioureas as Radical Scavengers 
Thioureas will readily react with hydroxyl radicals and hydrogen 
peroxide.92 Superoxide radicals can abstract a single hydrogen from either 
nitrogen of a thiourea group in aqueous media which can then rearrange 
to form a sulfhydryl.93,94 The ROS then reacts with water to form 
hydroxide ions. Thiourea will also react with hydrogen peroxide to 
generate formamidinesulfinic acid, 46.95 
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Scheme 7 Reaction of the thiourea group with hydrogen peroxide 
 
 
 
Thiourea has been used as an experimental tool to investigate 
fluoroquinolone mechanisms of action.48 The thiourea fluoroquinolone 
conjugates were designed with this in mind, to try to prevent the ROS 
from causing phototoxicity in vivo.  
 
1.4.3 Fluoroquinolone-Thiourea Conjugates 
Previously, ciprofloxacin-thiourea conjugates 47, 48, 49, have been 
synthesised by esterifying the carboxylic acid group and functionalising 
the piperazine ring.36 When tested against E. coli, most of these molecules 
did not retain the efficacy of ciprofloxacin, they had a reduced zone of 
inhibition (ZI). It was thought that the altering of the carboxylic acid could 
interfere with the formation of the ciprofloxacin-Mg2+-enzyme water 
bridge and decrease the binding affinity.36 
 
51 
 
 
Figure 11 Previously synthesised Ciprofloxacin-thiourea conjugates. R = H, 2-CH3, 3-CH3, 
4-CH3, 2-NO2, 3-NO2, 4-NO2, 2-OCH3, 4-OCH3, 3-Cl, 4-Cl, 4-COOH36 
 
However, one molecule, 50, increased the ZI against the Gram-negative E. 
coli and decreased the ZI against the Gram-positive S. aureus compared to 
ciprofloxacin. In fact, all molecules 47-49 had this effect, though not to the 
same extent.36 This suggests that some feature of Gram-negative bacteria 
increases the efficiency of uptake of the thiourea group in Gram-negative 
bacteria.  
 
 
 
52 
 
Investigations have also been carried out on forming dimers of 
Ciprofloxacin, 51, and Norfloxacin, 52, using thioureas. Polyethylene 
Glycol (PEG) linkers have been shown to increase lipophilicity and hence 
bioavailability of antibiotics, without decreasing the efficacy too much in 
vitro.64 PEG has also been used to form ciprofloxacin slow release 
liposomes that would circulate the blood stream and diffuse ciprofloxacin 
out into the surrounding tissue.96 
 
 
 
These type of ciprofloxacin dimers appear to have an upper limit to the 
molecular weight as larger dimers appeared to be generally less effective. 
The OmpF porin that ciprofloxacin diffuses through has a molecular 
weight limit of around 600 daltons.20 
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1.5 Project Overview 
 
The initial aim of the project was to synthesise a small library of N-
thioureido phenyl ciprofloxacin conjugate compounds. Fluoroquinolone 
conjugates have been shown to be a very effective class of antibiotics.97–99 
The phenyl thiourea group was chosen as a target due to the evidence for 
the binding to DNA Gyrase at a separate site to the fluoroquinolones.91 
We hoped that the two groups would act synergistically, and each help 
localise the other to the respective target binding site of the protein. 
There is proven track record of thiourea modifications at the C3 carboxyl 
group36 affecting the activity of Ciprofloxacin so we felt there was merit in 
investigating similar conjugations at the piperazine.97 
 
Before synthesising and screening the thiourea conjugates, it was realised 
that their activity was reduced in comparison to the parent antibiotic, 
ciprofloxacin. As biolabile linkers, the disulfide bridge in particular, is a 
well-studied area, hence it was decided to investigate a system that could 
release the antibiotic in the cytoplasm of the bacterial cell.67 Initially, the 
target molecule was chosen as the ciprofloxacin dimer due to the previous 
promising examples discussed above. It was believed that this would be a 
suitable first target due to the simplicity in the design and it would allow 
investigation into the cleavage of the disulfide before proceeding with the 
ultimate aim of combining thioureas and ciprofloxacin linked by a disulfide 
biolabile link.  
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2.0 Results and Discussion of Synthesis and Biological Screening 
of the Thiourea Linked Ciprofloxacin Conjugates 
 
2.1 Synthesis of Thiourea Linked Ciprofloxacin Conjugates 
 
Phenyl thioureas have been noted to inhibit one of the same intracellular 
targets as ciprofloxacin, DNA Gyrase, by binding at a separate site.43,91 The 
thiourea groups could react with the ROS produced by the ciprofloxacin,92 
which would decrease its efficacy. It was thought that the thiourea groups 
could also remove the phototoxic effects of ciprofloxacin and produce a 
safer antibiotic.  
 
Conjugation of a thiourea to the terminal carboxylic acid has been shown 
to decrease efficacy relative to ciprofloxacin.36 Attaching the group to the 
nitrogen of the piperidine ring was decided to be the best approach as this 
position is not part of the pharmacophore.24 A variety of such conjugates 
have been synthesised with nitrogen as an attachment point and although 
activity was reduced, it was still present.66,65 As thiourea is a DNA gyrase 
binding moiety itself it was theorised that it could counteract the loss of 
efficacy seen in other modifications of this type.91  
 
 
Figure 12 Structure of ciprofloxacin-thiourea conjugates. X = H, Cl Y = H, Cl, F 
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The designed conjugates have a phenyl thiourea group linked to 
ciprofloxacin via a glycine spacer, 53, as shown in Figure 12. These spacers 
have been shown to be most effective against Gram-negative strains 
when used in ciprofloxacin-citrate conjugate systems, though overall 
efficacy was reduced.45 The intended synthesis is shown in Scheme 8. 
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Scheme 8 Proposed synthesis for a ciprofloxacin-thiourea conjugate  
57 
 
 
As a point of variety, the antimicrobial effects of halogen substituents on 
the phenyl ring were explored. These combinations were selected based 
on the observations of A. Bielenica et al. on a 3-trifluoromethylphenyl 
thiourea conjugate. The conjugate with the lowest MIC was the 3-chloro-
4-fluorophenyl species, 45.90  
 
 
 
This prompted us to investigate the effects of varying the positions of 
halogens on the ring as this has been shown to affect the activities of 
phenyl thiourea conjugates. In order to do this, compounds 62-65 were 
made. The synthesis of each is discussed in later paragraphs. 36,90,100 
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2.1.1 Methylation of Ciprofloxacin 
The first step in the synthesis requires the protection of the carboxylic 
acid group of ciprofloxacin. This is done for two reasons, first removing 
the zwitterionic nature of ciprofloxacin making it easier to dissolve in 
organic solvents.101 It also prevents any competing coupling reactions 
when amidation is undertaken.102 The methyl protecting group was 
chosen as it is base labile103, so orthogonal to the Boc protecting group on 
the nitrogen of the glycine spacer. Methylation was performed as shown 
in Scheme 9. 
 
 
Scheme 9 Methylation of ciprofloxacin 
 
Ciprofloxacin methanoate, 54, was isolated in 83 % yield. The successful 
synthesis of 54 was supported by 1H NMR analysis with a signal at 3.91 
ppm of relative integration of 3 present in the spectrum. In addition, a 
signal at 51.95 ppm was observed in the 13C NMR spectrum, both signals 
can be attributed to the methyl group of the ester formed. IR 
spectrometric analysis showed a new peak at 1720 cm-1. Additionally, 
mass spectrometric analysis showed a peak at 346.1568 corresponding to 
([C18H20FN3O3+H]+  
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2.1.2 Conjugation of Me-Ciprofloxacin with N-Boc protected Glycine 
With the protected ciprofloxacin in hand, conjugation to the spacer was 
explored. EDC-mediated coupling to commercially available N-Boc glycine, 
55, was performed as shown in Scheme 10. 
 
 
Scheme 10 EDC-mediated coupling of Me-ciprofloxacin to N-Boc glycine 
 
Ciprofloxacin methanoate was reacted with N-Boc glycine using EDC as a 
coupling agent, with DMAP and DIPEA conjugate. 56 was isolated by 
column chromatography in 55% yield. Successful synthesis of 56 was 
supported by the observation of a peak at 1.46 ppm with a relative 
integration of 9 and a peak at 4.04 ppm of relative integration of 2 in the 
1H NMR trace. These signals correspond to the t-butyl protons of the Boc 
group and the alpha protons of the glycine respectively. Signals observed 
in the 13C spectrum at 41.72 ppm and 169.18 ppm correspond to the 
alpha carbon and the amide carbonyl of the glycine respectively. Signals 
corresponding to the Boc group were also observed at 169.18 ppm, 79.80 
ppm and 28.30 ppm.  Mass spectrometric analysis revealed a signal at 
503.2306 corresponding to ([C25H31FN4O6+H]+ 
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2.1.3 Boc Cleavage 
The terminal Boc group was removed with 20% trifluoroacetic acid (TFA) 
in dichloromethane, as seen in Scheme 11. 
 
 
Scheme 11 Boc cleavage of 56 
 
The deprotected product, 57, was isolated in quantitative yields and the 
1H NMR spectrum showed the expected loss of peaks at 1.46ppm, and the 
peaks at 169.18ppm, 79.80ppm and 28.30ppm in the 13C NMR were also 
absent.  The TFA counterion is observed in the 19F NMR at -73.46ppm. No 
residual free TFA was present as the other signals in the 19F NMR trace 
were due to the fluorine present on ciprofloxacin at -124.43 – -124.49 
ppm. Mass spectrometric analysis revealed a peak at 403.1776 
corresponding to ([C20H24F1N4O4+H]+ 
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2.1.4 Synthesis of Ciprofloxacin-Thiourea Conjugates 
The next step was the construction of the thiourea moiety Scheme 12. 
 
 
Scheme 12 Reaction of 57 with isothiocyanate. Conjugates 58 X = H, Y = H 59 X = Cl, Y = 
F 60 X = Cl, Y = H 61 X = H, Y = Cl   
 
The reaction was carried out with Et3N in MeCN. MeCN was chosen as a 
solvent due to the solubility of the isothiocyanates used and the 
corresponding insolubility of the resultant product, allowing isolation by 
simple filtration. The relevant data is shown in Table 1 and Table 2. 
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Compound  Isolated  
Yield / % 
IR Spectrometry values 
for the thiourea / cm-1 
ESI-MS m/z 
observed 
Molecular ion 
58 96 3409 538.1910 [C27H28FN5O4S +H]+ 
59 85 3293 590.1442 [C27H26ClF2N5O4S +H]+ 
60 87 3281 572.1538 [C27H27ClFN5O4S +H]+ 
61 81 3279 572.1538 [C27H27ClFN5O4S+H]+ 
 
Table 1 Yields, IR wavenumbers and mass spectrometric analysis of Compounds 58-61 
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Compound Key 1H NMR 
signals 
observed / 
ppm 
Assignment Key 13C 
NMR signals 
observed / 
ppm 
Assignment 
58 10.02 
7.83 
7.51 
7.34 
7.12 
NH thiourea 
NH thiourea 
CH phenyl 
CH phenyl 
CH phenyl 
171.58 
139.18 
128.69 
124.45 
122.80 
Thiourea carbonyl 
Phenyl 
Phenyl 
Phenyl 
Phenyl 
59 10.05 
8.01 
7.93 
7.37-7.39 
NH thiourea 
NH thiourea 
CH phenyl 
CH phenyl 
171.54 
160.68 
124.41 
124.35 
124.29 
118.82 
116.65 
Thiourea carbonyl 
Phenyl 
Phenyl 
Phenyl 
Phenyl 
Phenyl 
Phenyl 
60 10.20 
8.05 
7.88 
7.32-7.40 
7.14 
NH thiourea 
NH thiourea 
CH phenyl 
CH phenyl 
CH phenyl 
171.53 
141.06 
132.70 
130.00 
123.52 
121.56 
120.59 
Thiourea carbonyl 
Phenyl 
Phenyl 
Phenyl 
Phenyl 
Phenyl 
Phenyl 
61 10.13 
7.96 
7.59 
7.37 
NH thiourea 
NH thiourea 
CH phenyl 
CH phenyl 
171.53 
138.43 
128.44 
127.76 
124.10 
Thiourea carbonyl 
Phenyl 
Phenyl 
Phenyl 
Phenyl 
 
Table 2 Relevant spectroscopic data on the synthesis of Compounds 58-61 
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The successful synthesis of the thiourea conjugates 58-61 is supported by 
the information above in Table 1 and Table 2.  
 
2.1.5 Carboxylic Acid Deprotection 
The final stage of the reaction scheme was base hydrolysis of the methyl 
ester on the C-terminal carboxylic acid. NaOH dissolved in 
dimethylformamide (DMF) was used, as shown in Scheme 13. After 
deprotection, subsequent acidification resulted in deprotected conjugate 
precipitating and it could be isolated without any further purification. The 
relevant NMR peaks lost in the analysis of the products are shown in Table 
3. Elemental analysis was performed, and the results are shown in Table 
4. Trace amounts of DMF were detected in the 1H NMR spectra of some of 
the samples. The percentage level of DMF in each sample has been 
calculated from the integration of the peaks relative to the thiourea 
conjugate in the NMR spectrum and is shown in Table 4. 
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Scheme 13 Deprotection of the C-terminal carboxylic acid. Conjugates 58 X = H, Y = H 59 
X = Cl, Y = F 60 X = Cl, Y = H 61 X = H, Y = Cl.  Deprotected conjugates 62 X = H, Y = H 63 X 
= Cl, Y = F 64 X = Cl, Y = H 65 X = H, Y = Cl   
 
Compound Isolated 
Yield / % 
Key 1H NMR 
signals 
absent / 
ppm 
Key 13C 
NMR signals 
absent / 
ppm 
ESI-MS m/z 
observed 
62 52 3.73 51.28 524.1772 
63 49 3.73 51.28 576.1280 
64 75 3.73 51.28 572.1538 
65 40 3.73 51.30 572.1538 
Table 3 Yields and spectrometric data for the synthesis of Compounds 62-65 
67 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4 Spectrometric and elemental analysis results for Compounds 62-65 
 
The successful deprotection of each of 58-61 to generate 62-65 was 
supported by the disappearance of the peaks corresponding to the methyl 
groups from both 1H and 13C NMR spectra of the starting material. The 
deprotection reaction was shown to be complete by TLC. The loss of yield 
is due to the incomplete crystallisation when acid was added. The 
conjugates have multiple protonation sites on the ciprofloxacin and 
thiourea moieties and as a result could not be fully crystallised out of 
solution. The elemental analysis was calculated to be consistent with the 
adjusted formulae. 
Compound Calculated 
Elemental 
Analysis / 
% 
Observed 
Elemental 
analysis / 
% 
Percentage 
of DMF 
contaminant 
/ % 
62 C 58.73 
H 5.10 
N 13.17 
C 58.59 
H 4.98 
N 13.08 
2 
63 C 52.57 
H 4.41 
N 11.79 
 
C 52.29 
H 4.11 
N 11.69 
1 
64 C 53.31 
H 4.41 
N 11.96 
 
C 53.29 
H 4.35 
N 11.90 
2 
65 C 52.66 
H 4.39 
N 11.67 
C 53.81 
H 4.25 
N 11.67 
0 
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2.2 Biological Screening of Ciprofloxacin Thiourea Conjugates 
 
 
 
Conjugates 62-65, were screened for antimicrobial activity against 
BW25113 wt E.coli in Lysogenic Broth (LB). Ciprofloxacin was also tested 
as a direct comparison as the parent antibiotic. Due to the synthesis 
leaving trace amounts of DMF, that was also run as a control.  
 
Below is shown the general plate layout used for these experiments in 
Table 5, as well as the stock solutions used to fill the wells.  Each stock 
solution was made up using the calculated mass from the elemental 
analysis and dissolved in DMSO. The triplicate repeats function as 
biological controls with each being grown from a different bacterial colony 
overnight in LB at 37°C.  The three cultures were corrected to an OD650 of 
2.0 before inoculation.   
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Table 5 Well lay out and stock solutions for the biological screening of Compounds 62-
65 
 
The outer wells of the plate were filled with 200µl of deionised water to 
minimise evaporation effects over the 20 hours. Into each blank well was 
placed 196µl of LB and 4µl of DMSO. Into each test well was placed 191µl 
of LB, 4µl of drug stock solution of the appropriate concentration and 5 µl 
of OD corrected bacterial culture.  The blank wells were averaged and 
subtracted from the other values to control for any effect of DMSO or LB 
on the OD650 values. 
 
Since the NMR spectra of the thiourea conjugates showed trace amounts 
of DMF in them, a control was run to evaluate the effect of DMF on 
bacterial growth. The stock concentration of DMF was calculated to 
equate to the amount of DMF in the most heavily contaminated conjugate 
when 10µM concentration of the conjugate is used in the screening. The 
results are shown in Figure 13. 
Well Conc / µM Stock Conc / µM
0 0
2 10
4 20
6 30
8 40
10 50
1 2 3 4 5 6 7 8 9 10 11 12
A H2O H2O H2O H2O H2O H2O H2O H2O H2O H2O H2O H2O
B H2O Drug 1 Drug 1 Drug 1 Drug 2 Drug 2 Drug 2 Drug 3 Drug 3 Drug 3 Blank H2O
C H2O Drug 1 Drug 1 Drug 1 Drug 2 Drug 2 Drug 2 Drug 3 Drug 3 Drug 3 Blank H2O
D H2O Drug 1 Drug 1 Drug 1 Drug 2 Drug 2 Drug 2 Drug 3 Drug 3 Drug 3 Blank H2O
E H2O Drug 1 Drug 1 Drug 1 Drug 2 Drug 2 Drug 2 Drug 3 Drug 3 Drug 3 DMF H2O
F H2O Drug 1 Drug 1 Drug 1 Drug 2 Drug 2 Drug 2 Drug 3 Drug 3 Drug 3 DMF H2O
G H2O Drug 1 Drug 1 Drug 1 Drug 2 Drug 2 Drug 2 Drug 3 Drug 3 Drug 3 DMF H2O
H H2O H2O H2O H2O H2O H2O H2O H2O H2O H2O H2O H2O
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Figure 13 Bacterial growth curve of E. coli BW25113 with 0.26 μM 
 DMF additive. Error bars are ± standard deviation of three biological replicates 
 
As can be seen, DMF has no discernible effect on bacterial growth.  
 
The results of the thiourea conjugate growth assays at increasing 
concentration are shown in Figures 14-19.  
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Figure 14 Control bacterial growth curve of BW25113 strain of E. coli. Error bars are ± 
standard deviation of three biological replicates 
 
 
Figure 15 Bacterial growth curve of E. coli BW25113 with 2.0 μM 
additives. Error bars are ± standard deviation of three biological replicates 
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Figure 16 Bacterial growth curve of E. coli BW25113 with 4.0 μM 
additives. Error bars are ± standard deviation of three biological replicates 
 
 
 
Figure 17 Bacterial growth curve of E. coli BW25113 with 6.0 μM 
additives. Error bars are ± standard deviation of three biological replicates 
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Figure 18 Bacterial growth curve of E. coli BW25113 with 8.0 μM 
additives. Error bars are ± standard deviation of three biological replicates 
 
 
 
Figure 19 Bacterial growth curve of E. coli BW25113 with 10.0 μM 
additives. Error bars are ± standard deviation of three biological replicates 
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As can be seen, all four thiourea conjugates have a concentration 
dependent effect on bacterial growth. The maximum OD650 reached in the 
control experiment was around 1.1, however, the maximum OD650 
reached decreases as concentration increases. 
 
There is a significant drop in max OD650 when the concentration is 
increased to 6 µM and no significant further change with higher 
concentrations. The data suggests the MIC for these thiourea conjugates 
is between 4 µM and 6 µM. This is a large drop in efficacy from 
Ciprofloxacin which has a MIC of 0 µM to 2 µM in these studies. Since the 
activity of Ciprofloxacin is due to the formation of a tight, specific enzyme 
complex,24 the additional steric bulk could be inhibiting the binding as 
observed in other studies.56,68,85,99 In addition, the piperazine’s function is 
to prevent the drug being effluxed. The thiourea modification could be 
blocking this function resulting in a lowered intracellular concentration of 
the conjugates.   
 
At all concentrations, the thiourea conjugates appear to have a lag time of 
around three hours before beginning to influence the rate of growth of 
the bacteria. This lag time is much longer than the Ciprofloxacin 
experiments, suggesting that the thiourea modifications are slowing down 
the rate of uptake of the drug into the cell. The zwitterionic nature of 
ciprofloxacin has been removed by the modifications. Removal of the 
ionisable group increases the lipophilicity, and hence the ability to diffuse 
through the lipid bilayer.17 However the porins in the bacterial outer 
membrane transport have a higher affinity for charged molecules so the 
rate of uptake through the OmpF porin could be slowed.19 The molecular 
weight is still under the cut-off for OmpF, though the shape of the 
molecule may be incompatible with the porin.18 
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The four different thiourea conjugates show no significant difference in 
efficacy as can be seen in Figure 20. As all error bars overlap they can be 
assumed to be, within the margin of error of the experiment, the same. 
No difference can be seen by varying the halogens or substitution 
positions on the phenyl ring, albeit with a limited number of examples.  
 
 
Figure 20 OD650 values for all thiourea conjugates at 10 hours. Error bars are ± standard 
deviation of three biological replicates 
 
These experiments showed that the thiourea modification was decreasing 
the efficacy of the parent antibiotic, ciprofloxacin. To explore the 
interaction of the conjugates with the intracellular target, a DNA gyrase 
assay was performed on a representative conjugate 62. 
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2.3 DNA Gyrase Assay of Conjugate 62 
 
DNA Gyrase binding assays were used to explore whether the observed 
decrease in antimicrobial activity was, at least partly, due to decreased 
binding affinity to the target DNA gyrase. A negative control with no 
added DNA gyrase and a positive control with no added inhibitor were 
included.  
 
Relaxed plasmid pBR322 DNA was incubated with E. coli DNA Gyrase in 
the presence of various concentrations of 62 to investigate its ability to 
inhibit the supercoiling activity of Gyrase. As DMSO, a known inhibitor of 
Gyrase,104 was used to solubilise the compound, a DMSO control was 
included.  The contents of each well are listed in Table 6.  
 
  Positive Negative 
Test 
Wells 
DMSO 
control 
H2O / µL 21.5 23.5 20.5 20.5 
pBr322 / µL 0.5 0.5 0.5 0.5 
Assay Buffer / µL 6 6 6 6 
Drug Stock / µL 0 0 1 0 
DMSO / µL 0 0 0 1 
Gyrase Aliquot / µL 2 0 2 2 
 
Stock Drug Conc / 
µM 
Assay Drug Conc / 
µM 
15 0.5 
30 1 
150 5 
300 10 
600 20 
 
Table 6 Contents of each experiment in the DNA gyrase assay of Compound 62 and the 
stock solutions 
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After an incubation time of 30 minutes, the reaction was stopped with a 
50:50 mix of isoamyl alcohol and chloroform. Each sample was loaded into 
a well in a 1 % w/v agarose gel and run at 75 V for 90 minutes. The gel was 
then stained using 10 µL SYBR SAFE in 100 mL TBE buffer for 60 minutes, 
destained in TBE buffer and imaged. The picture was enhanced and is 
presented in Figure 21. 
µM 
 
Figure 21 DNA gyrase assay of compound 62 at different concentrations with positive 
control (+ve) – 2 μL DNA gyrase and 0.0 μM of drug, negative control (-ve) – no DNA 
gyrase and 0.0 μM of drug and a DMSO control. OC- open circular and SC- supercoiled 
plasmid 
 
The open circular (OC) plasmid moves more slowly through the agarose 
gel as it presents more surface area to the direction of movement. The 
supercoiled (SC) DNA moves more quickly as it is smaller. Incubating the 
OC plasmid with Gyrase will convert it into the SC form over time, and the 
inhibitor will prevent the SC band formed. More effective inhibitors and 
higher concentrations result in a fainter SC band.   
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The conjugate investigated has some DNA Gyrase binding affinity. The 
DMSO control indicates that the DMSO is having a small inhibitory effect. 
However, as the drug concentration increases, the supercoiled band is 
seen to fade. Ciprofloxacin shows complete inhibition of Gyrase activity 
with a concentration of 0.5 µM.66 For 62 the supercoiled band fades at 10 
µM.  This data suggests that the binding affinity has been reduced with 
the thiourea modifications, possibly due to the increased steric bulk of the 
molecule. Previous work in the Duhme-Klair/ Routledge laboratory has 
found similar results when modifying ciprofloxacin with sterically bulky 
groups. 65,66 
 
2.4 Conclusions 
 
Thiourea moieties has been attached via a non-biolabile linker to 
ciprofloxacin. It has been demonstrated that these modifications have 
slowed uptake into the cell, as seen by the lag in the growth assays before 
growth is being inhibited, and that the binding affinity for DNA gyrase has 
also been reduced, as seen in the gel assays.  
 
The complex formed when ciprofloxacin binds to DNA gyrase is known to 
be tight and specific. The increased steric bulk of 62 could be interfering 
with the formation of this complex and there is no enhanced binding to 
gyrase with the thiourea present as proposed. Another possibility is that 
the thiourea may be binding at an alternate site on the enzyme and 
preventing the more effective ciprofloxacin from reaching its binding site. 
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3.0 Results and Discussion of The Synthesis and Biological 
Screening of a Biolabile Ciprofloxacin Dimer 
 
As explored in the previous chapter, it was found that conjugating a 
thiourea moiety to ciprofloxacin with a non-biolabile linker resulted in 
reduced bactericidal activity and DNA gyrase inhibition. It was theorised 
that using the biolabile linker to link the two moieties could prevent these 
negative effects, as the linker would cleave to release the two active 
moieties to act independently.67 The disulfide bridge was chosen as it is 
proven to be stable in the extracellular medium in humans and cleaves in 
the intracellular medium of bacteria.84  
 
It was decided to explore the application of a biolabile linker by the 
synthesis of a ciprofloxacin dimer as the effect of linker would be easily 
comparable to the monomer, without the complication of the thiourea. 
The formation of ethylene sulphide67 as the link cleaved would potentially 
be quite slow, so the rate of cleavage needed investigating.  
 
3.1 Ciprofloxacin Dimer Synthesis 
 
A dimer of Ciprofloxacin was chosen as an initial target molecule, with a 
disulfide bridge link 66. The dimer was designed to be stable in the 
extracellular medium84 and periplasm.78 As the carboxylic acid is modified 
it would no longer be charged, meaning the molecule would be less 
hydrophilic and hence have the potential to cross the lipid bilayer more 
rapidly than the monomer.16–18 Once the dimer entered the cytoplasm of 
the bacterium, it would be cleaved by the bacterium’s endogenous 
reductive pathways, such as reacting with glutathione and free cysteine 
residues.71,77  As Jain et al. also note, the carboxylic acid groups on 
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ciprofloxacin make it an excellent candidate for disulfide attachment via 
an ester link. 67 The cleavage of 66 is shown in Scheme 14.  
 
 
Scheme 14 Proposed mechanism of ciprofloxacin-disulfide dimer cleavage.67 R = 
glutathione or cysteine 
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The N-terminal piperazine will be protected to prevent competing 
coupling reactions. An acid labile tert-butyloxycarbonyl (Boc) protecting 
group was chosen as the disulfide was prone to cleavage under basic 
conditions.65 Attaching the linker to the free carboxylic acid group would 
allow the dimer to cleave in the cytoplasm, releasing ciprofloxacin as seen 
in Scheme 14 above.  The proposed synthesis of 66 is shown in Scheme 
15. 
 
 
82 
 
 
Scheme 15 Proposed synthesis of 66 
 
83 
 
3.1.1 N-Boc protection of Ciprofloxacin 
 
The first step was the protection of the N-terminus of ciprofloxacin with a 
Boc group. The reaction is shown in Scheme 16.  
 
 
Scheme 16 Boc protection of ciprofloxacin 
 
The successful synthesis of 67 was supported by 1H analysis with a peak at 
1.50 ppm with relative integration of 9 observed in the spectrum. The 
presence of a Boc group was also supported by peaks at 166.87 ppm, 80.3 
ppm and 28.36 ppm observed in the 13C NMR spectrum. In addition, a 
peak at 432.1923 corresponding to [C22H26FN3O5+H]+ was present in the 
mass  spectrum.  
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3.1.2 HATU-coupled Dimerisation of N-Boc Ciprofloxacin via a Disulfide 
Linker 
With the protected ciprofloxacin in hand, the construction of the disulfide 
link was investigated, Scheme 17. 
 
 
Scheme 17 Formation of the protected ciprofloxacin dimer, 68 
 
A variety of coupling agents were investigated. Initially members of the 
carbodiimide family were tested. Both 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (EDC) and N,N'-dicyclohexylcarbodiimide (DCC) failed to give 
the desired disulfide. There were no triplet peaks that suggest the 
presence of the bridging carbon chains in the 1H NMR, nor was the dimer 
seen in mass spectrometric analysis. Instead, in mass spectrometric 
analysis, a peak was seen at 587.3376 that matched the rearranged N-
acylurea, 70, often seen with carbodiimides105 and shown in Scheme 18. 
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Scheme 18 Carbodiimide intermediate rearrangement from O-acylurea to unreactive N-
acylurea using DCC as an example. R = ciprofloxacin 
 
Propyl phosphonic anhydride (T3P) was the next coupling agent 
investigated and was also unsuccessful. T3P has come to prominence due 
to its ability to prevent the epimerisation seen with the carbodiimide 
coupling agents. Alongside this, it is known for a facile work up due to 
water soluble by-products, its solubility in a range of organic and polar 
solvents, and its reactivity in mild reaction conditions.106  
 
 
 
The proposed reaction is shown in Scheme 19. After a 3-day reflux and an 
aqueous wash, only signals corresponding to the starting material was 
observed in the 1H spectrum of the crude material recovered after an 
aqueous wash to remove unreacted T3P.  
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Scheme 19 The unsuccessful proposed synthesis of the protected dimer using T3P 
 
Next, 1-[bis (dimethylamino) methylene]-1H-1,2,3-triazolo[4,5-b] 
pyridinium 3-oxid hexafluorophosphate (HATU) was investigated. The 
reaction can be seen in Scheme 20. 
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Scheme 20 Successful synthesis of 68 
 
Analysis of the unpurified reaction mixture suggested the presence of 
three ciprofloxacin-containing compounds, judging from the singlet peaks 
at 8.45 ppm, 8.55 ppm and 8.59 ppm with relative integrations of 1.00, 
0.36 and 0.14 respectively. Several sets of triplet peaks were observed to 
overlap that correspond to the CH2 groups in the disulfide bridge. The 
disulfide bridge peaks of 2-hydroxyethyl disulfide appear at 3.88 ppm and 
2.87 ppm, which are absent from the crude spectrum.  It was decided to 
try to isolate these separate species but attempts using column 
chromatography failed. In all cases it was seen that the multiple 
ciprofloxacin species co-eluted in the solvent mixtures. The stationary and 
mobile phases that were investigated are noted in Table 7.  
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TABLE 7 Unsuccessful solvent systems investigated to purify Compound 68  
 
 With the lack of success with column chromatography the next technique 
investigated was preparatory High-Performance Liquid Chromatography 
(HPLC) as described in the Experimental Chapter. The HPLC method 
successfully managed to purify the desired product 68 although at 
extremely low yield. The HPLC trace is shown in Figure 22. 
 
Attempt Stationary 
Phase 
Solvent 1 Solvent 2 Additives 
1 Silica 100 % EtOAc - - 
2 Silica 90 % CHCl3 10 % MeOH - 
5 Silica 95 % EtOAc 5 % MeOH - 
6 Silica 97 % CHCl3 3 % MeOH - 
7 Alumina 50 % MeCN  50 % CHCl3 - 
8 Alumina 80 % MeCN 20 % CHCl3 0.1% NH3 
9 Silica 100% MeCN - - 
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Figure 22 HPLC trace for the isolation and purification of compound 68, which eluted at 
11 minutes 
 
The successful synthesis of 68 was supported by 1H NMR spectroscopy. 
The appearance in the spectrum of triplets at 4.55 ppm and 3.09 ppm 
each with a relative integration of 4H corresponding to the CH2 groups in 
the disulfide bridge. The 13C NMR also showed peaks at 62.35 ppm and 
37.37 ppm corresponding to these CH2 groups too. Mass spectrometric 
analysis also showed a peak at m/z = 1003.3514 which corresponds to the 
presence of [C48H58F2N6O10S2+Na]+ The target molecule was synthesised 
with a 5.3 % mass recovery after HPLC purification. 
 
As mentioned above the overlapping sections of the 1H NMR made it 
impossible to determine the relative integrations of the different 
ciprofloxacin-disulfide species in the reaction mixture before HPLC. The 
low mass recovery could be due to an incomplete reaction, with the dimer 
being a minor species hidden under the other side products in the 1H NMR 
spectrum. It is also possible that the product was lost during the filtration 
process or on the HPLC column itself.  
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3.1.3 HCl deprotection of the Dimer 
As shown in Scheme 21, protected dimer 68 was initially deprotected with 
TFA and isolated as the TFA salt. However TFA ions are known to perturb 
screening results107 so ion exchange to the chloride salt was undertaken. 
To exchange ions the solid was dissolved in aqueous HCl (10 mM) and 
then freeze dried. Unfortunately, this ion exchange resulted in disulphide 
cleavage, as seen by the disappearance of the triplets at 4.55 ppm and 
3.09 ppm in the 1H NMR spectrum.  
 
 
Scheme 21 Deprotection with TFA and ion exchange of compound 72 
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What proved more successful was using HCl mediated deprotection. The 
reaction was found to be complete in under 10 minutes as judged by TLC 
analysis. This process can be seen in Scheme 22.  
 
 
Scheme 22 HCl mediated deprotection of 68 
 
The success of the deprotection was supported by the disappearance of 
the peaks at 1.50 ppm, relative integration 18, in the 1H NMR spectrum. 
The presence of the triplets at 4.41 ppm and 3.09 ppm in the 1H NMR 
spectrum and the corresponding peaks at 61.82 ppm and 36.68 ppm in 
the 13C NMR spectrum indicate that the disulphide bridge remained intact. 
The mass spectrometric analysis also showed a peak at m/z 781.2662 
corresponding to [C38H46Cl2F2N6O6S2+H]+, the intact dimer. 
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3.2 Biological Screening of Ciprofloxacin Dimer 
 
 
 
The deprotected dimer, 66, was screened against wt B25113 E. coli to 
evaluate its potential as an antimicrobial agent. Ciprofloxacin was also 
tested as a positive control. The concentrations were calculated assuming 
100% purity.  
 
The plate layout is shown in Table 8. Compound 66 was loaded in 
deuterated DMSO and the Ciprofloxacin was loaded in DMSO, so blanks 
were included for both DMSO and d6-DMSO.  
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Well Conc / 
µM 
Stock Conc / 
µM 
0 0 
2 10 
4 20 
6 30 
8 40 
10 50 
 
Table 8 Plate layout and stock solutions used in the biological screening of Compound 
66 
 
The outer wells of the plate were filled with 200 µL of deionised water to 
try and minimise evaporation effects over the 20 hours. Into each blank 
well was placed 196 µL of LB and 4 µL of DMSO or d6-DMSO as 
appropriate. Into each test well was placed 191 µL of LB, 4 µL of drug 
stock solution of the appropriate concentration and 5 µL of OD corrected 
bacterial culture.   
 
1 2 3 4 5 6 7 8 9 10 11 12
A H2O H2O H2O H2O H2O H2O H2O H2O H2O H2O H2O H2O
B H2O Dimer Dimer Dimer Ciprofloxacin Ciprofloxacin Ciprofloxacin Blank DMSO H2O
C H2O Dimer Dimer Dimer Ciprofloxacin Ciprofloxacin Ciprofloxacin Blank DMSO H2O
D H2O Dimer Dimer Dimer Ciprofloxacin Ciprofloxacin Ciprofloxacin Blank DMSO H2O
E H2O Dimer Dimer Dimer Ciprofloxacin Ciprofloxacin Ciprofloxacin Blank d6-DMSO H2O
F H2O Dimer Dimer Dimer Ciprofloxacin Ciprofloxacin Ciprofloxacin Blank d6-DMSO H2O
G H2O Dimer Dimer Dimer Ciprofloxacin Ciprofloxacin Ciprofloxacin Blank d6-DMSO H2O
H H2O H2O H2O H2O H2O H2O H2O H2O H2O H2O H2O H2O
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Figure 23 Bacterial growth curve of E. coli BW25113 with varying concentrations of  
 additive. Error bars are ± standard deviation of three biological replicates 
 
The data shows there is no significant concentration dependence for the 
first 10 hours of the experiment. It is only in the latter half of the 
experiment, and at higher concentrations that we see any significant 
changes in bacterial growth. The large lag phase, much longer than that of 
ciprofloxacin, suggests that the rate of target delivery has been drastically 
reduced. It is unknown at this point whether the lag phase represents 
slow uptake of the prodrug before activation. The molecular weight (781 
Daltons) is above the nominated maximum of the OmpF porin (around 
600 Daltons)19 so this uptake pathway is likely to be inhibited. It could be 
the slow breakdown of the disulfide linker once inside the cell, but it is 
generally believed that this process is rapid.74,84 It is unlikely to be the 
slow breakdown of the disulphide outside of the cell and release of free 
ciprofloxacin into the extracellular media as there are no reducing 
components in LB buffer. 
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3.3 Conclusions 
 
The successful synthesis of 66 was completed, albeit at low yield.  
Preparative HPLC was needed for the purification as the protected dimer 
68 could not be separated from other contaminants by standard silica 
chromatography. Due to the crude 1H NMR spectrum showing overlapping 
triplet peaks, it was impossible to determine whether the low yield was 
due to a low reaction yield or whether the mass was being lost in the 
HPLC process. 
 
The biological screening showed the molecule has some antimicrobial 
activity at very high concentrations and in the later stages of the 
experiment. These limited biological screening experiments did not show 
conclusively whether the disulphide is breaking down extracellularly in the 
media or in the cytoplasm. 
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3.4 Future Work 
 
The screening of 66 suggested that it was not inhibiting bacterial growth 
as quickly as the parent monomer, ciprofloxacin. However, in the later 
stages of the screening and at the higher drug concentrations, 66 was 
starting to have a bactericidal effect. Therefore, it would be prudent to 
run the experiment over a longer period, to investigate this lag phase in 
more detail. The rate of cleavage of the bridge could also be studied in 
vitro by monitoring the cleavage of the disulfide by glutathione. 
 
Once the ciprofloxacin dimer had been investigated, the next stage would 
be conjugating the phenyl thiourea groups discussed in the first section of 
the project to ciprofloxacin using the either the disulfide linker or other 
examples in the literature. These include but are not limited to the para-
aminobenzyl alcohol spacer108 and the tetrazine self-immolative linker.109 
As fluoroquinolones have a UV light-dependent ability to produce 
damaging ROS, these experiments could be performed in both the light 
and the dark to determine whether the released thiourea was having an 
inhibitory effect on this pathway.  
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4.0 Experimental 
 
4.1 General Chemistry Procedure 
 
4.1.1 Mass Spectrometry 
High resolution positive and negative ESI mass spectrometry was performed 
on a Thermo-Finnigan LCQ Spectrometer by Karl Heaton. 
 
4.1.2 NMR 
1H NMR (400 MHz), 13C NMR (100.6 MHz) and 19F NMR (376 MHz) spectra 
were acquired on a Jeol ECX400 spectrometer in the stated deuterated 
solvents. 13C NMR (125 MHz), 1H NMR (500 MHz) and 19F NMR (376 MHz)   
were acquired on a Bruker AV500 NMR spectrometer by Ben Coulson. 
Variable temperature NMR was performed on either a Jeol ECX400 
spectrometer. All chemical shifts (δ) are reported in parts per million 
(ppm) and referenced to the residual solvent. All J values are reported in 
Hertz to one decimal place. All 13C NMR spectra are proton de-coupled. 
The reference signals used were: 7.26 ppm and 77.16 ppm (CDCl3), 
3.31ppm ,2.50 ppm and 39.52 ppm (d6-DMSO). Chemical shifts for 
multiplets are reported from the middle of the multiplet. Multiplicity 
abbreviations are as follows: s = singlet; d = doublet; t = triplet; q = 
quartet; m = multiplet; dd = double doublet; dt = double triplet. All NMR 
assignments were aided by HMQC, COSY and HMBC experiments when 
required. All spectra were processed using ACD/NMR Processor Academic 
Edition software. 
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4.1.3 IR 
IR were recorded on a Perkin Elmer FT-IR Spectrum Two spectrometer 
(ATIR) in the region 4000-400 cm-1. 
 
4.1.4 HPLC 
Analytical HPLC was performed on a Shimadzu HPLC system (Prominence) 
with a LC-20AD pump, SIL-20A autosampler, DGU-20AS degasser, CTO-
20AC column oven, CBM-20A communication bus module and SPD-M20A 
diode array detector, using a SunFire C18 column (5 μm, 4.6 x 150 mm) 
with the specified eluent gradient.  
 
Preparative HPLC was performed on a Varian ProStar HPLC system with 
two 210 series pumps (25 mL), a 325 series UV detector, a model 701 
fraction collector and model 410 autosampler, using a SunFire Prep C18 
column (10 μm, 19 x 250 mm), with a SunFire C18 Prep Guard Cartridge (10 
µm, 19 mm X 10 mm) with the specified eluent gradient. The compound 
was dissolved in 2 mL of DCM and filtered through nylon filters with a 
0.45µm pore size before injection. Each injection was 200 µL. 
 
HPLC Analytical Method A 
Starting ratio is 65 : 35 MeCN + 0.1% Formic Acid (FA) : H2O + 0.1% FA. The 
gradient was raised over 12 minutes to 90 : 10 MeCN + 0.1% FA : H2O + 
0.1% FA and stayed constant for 30 seconds. The ratio was reduced to 65 : 
35 MeCN + 0.1% FA : H2O + 0.1% FA over 2.5 minutes. Total run time 15 
minutes. Flow rate 1 mL/min 
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HPLC Analytical Method B 
Starting ratio is 65 : 35 MeOH + 0.1% FA : H2O + 0.1% FA. The gradient was 
raised over 12 minutes to 90 : 10 MeOH + 0.1% FA : H2O + 0.1% FA and 
stayed constant for 30 seconds. The ratio was reduced to 65 : 35 MeOH + 
0.1% FA : H2O + 0.1% FA over 2.5 minutes. Total run time 15 minutes. Flow 
rate 1 mL/min 
 
HPLC Preparative Method A 
 
Injection volume of 200µl. Starting ratio is 65 : 35 MeCN + 0.1% Formic 
Acid (FA) : H2O + 0.1% FA. The gradient was raised over 12 minutes to 90 : 
10 MeCN + 0.1% FA : H2O + 0.1% FA and stayed constant for 30 seconds. 
The ratio was reduced to 65 : 35 MeCN + 0.1% FA : H2O + 0.1% FA over 2.5 
minutes. Total run time 15 minutes. Flow rate 1 mL/min 
 
4.1.5 Melting Points 
 
Uncorrected melting points were recorded using a Stuart Scientific SMP3 
instrument and are accurate to ± 0.05 °C. 
 
4.1.6 Elemental Analysis 
 
Elemental analysis was collected on an Exeter CE-440 elemental analyser 
by Dr Graeme McAllister. 
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4.1.7 Solvents 
 
Solvents were supplied by Aldrich, Fischer Scientific and VWR. Where 
required solvents were dried over 3 or 4 Å molecular sieves prior to use. 
Deionised water was used for all synthetic procedures. Dry solvents were 
obtained from departmental solvent stills (Prosolv MD 7 solvent purification 
system where solvents are passed through two columns of molecular sieves). 
For the EDC coupling reaction Acros Organics DMF AcroSeal® (99.8%, extra 
dry, over molecular sieves) was used. 
 
4.1.8 Reagents 
 
All chemical reagents were used as supplied unless otherwise stated and 
purchased from commercial suppliers: Acros, Alfa-Aesar, Fisher Scientific, 
Fluorochem, Sigma Aldrich. Chemicals were handled with appropriately 
according to their toxicity. 
 
4.1.9 Moisture-Sensitive Reactions 
 
Moisture-sensitive reactions were carried out under an atmosphere of N2. 
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4.1.10 Chromatography 
 
Analytical TLC used Merck silica gel 60 F254 aluminium-backed plates, with 
the specified eluent. All plates were visualised through UV light using 
Chromato-vue Model CC-10 at 254 nm or 365 nm, or stained with 
potassium permanganate. Column chromatography was performed with 
the specified eluent using Sigma-Aldrich high-purity grade silica gel, pore 
size 60 Å, 220-440 mesh particle size, 35-75 μm. 
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4.2 Chemical Synthesis 
 
4.2.1 Synthesis of Ciprofloxacin Phenyl Thiourea Conjugates 
 
4.2.1.1 Methyl-1-cyclopropyl-6-fluoro-4-oxo-7-(piperzin-1-yl)-1,4-
dihydroquinoline-3-carboxylate, 54 
 
 
Chemical Formula: C18H20FN3O3 
Molecular Weight: 345.3744 gmol-1 
Ciprofloxacin (1.91 g, 5.79 mmol) was dissolved in dry MeOH (100 mL) and 
cooled in ice. Thionyl chloride (8.38 mL g, 0.116 mol) was added dropwise 
with stirring, resulting in a yellow solution. This solution was heated under 
reflux for 17 hours. The solution was concentrated under reduced 
pressure giving a yellow oil. This was dissolved in sat. aq. K2CO3 (25 mL) 
and extracted with DCM (4 x 40 mL). The organic layers were combined 
and washed with water (40 mL) which was reextracted with DCM (3 x 40 
mL). The organic layers were combined and dried over anhydrous MgSO4. 
The solvent was removed under reduced pressure to give the title 
compound as a white crystalline solid. 
Yield: 
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1.657 g, 83 % 
m/z (ESI) 
346.1568 ([C18H20FN3O3+H]+ calculated mass 346.1561, 2.3 ppm mean 
error)  
1H NMR: (400 MHz, CDCl3, δH (ppm)): 
8.53 (s, 1H, H-11, CH), 8.01 (d, 3JF-H = 13.3 Hz, 1H, H-3, CH), 7.26 (d, 4JF-H = 
7.8 Hz, H-17, CH), 3.91 (s, 3H, H-25, CH3), 3.46-3.40 (m, 1H, H-13, 
cyclopropane, CH) 3.24-3.21 (m, 4H, H-21, H-23  piperazine, CH2), 3.10-
3.07 (m, 4H, H-20, H-24 piperazine, CH2), 1.34-1.29 (m, 2H, cyclopropane, 
CH2), 1.16-1.12 (m, 2H, cyclopropane, CH2) 
13C NMR: (100 MHz, CDCl3, δC (ppm)): 
172.9 (d, 4JC-F = 1.9 Hz, C-5), 166.3 (s, C-8), 153.3 (d, 1JC-F = 248.3 Hz, C-2) 
148.2 (s, C-11), 144.9 (d, 2JC-F = 10.5 Hz, C-18),  137.9 (s, C-7), 122.7 (d, 3JC-F 
= 7.7 Hz, C-4), 113.1 (d, 2JC-F = 22.0 Hz, C-3), 109.8 (s, C-16), 104.7 (d, 3JC-F = 
2.9 Hz, C-17), 52.0 (s, C-25), 51.1 (s, C-20, C-21, C-23, C-24), 51.1 (s, C-20, 
C-21, C-23, C-24), 45.9 (s, C-20, C-21, C-23, C-24), 34.5 (s, C-13), 8.0 (s, C-
14, C-15) 
19F NMR: (376 MHz, CDCl3, δF (ppm)): 
-123.4 (dd, 3JH-F = 13.3 Hz, 4JF-H = 7.8 Hz, F-1)  
IR: (cm-1) 
2950 (C-H), 2832 (C-H), 1720 (C=O, C-8, O-9), 1616 (C=O, C-5, O-6) 
Melting Point: (°C)  
Unable to be determined within the range of the instrument 
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4.2.1.2 Methyl 7-(4-((tert-butoxycarbonyl)glycyl)piperazin-1-yl)-1-
cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate, 56 
 
Chemical Formula: C25H31FN4O6 
Molecular Weight: 502.5434 gmol-1 
Compound 54 (1.099 g, 3.19 mmol), N-Boc-glycine (0.836 g, 4.77 mmol), 
and 4-dimethyl amino pyridine (DMAP) (0.363 g, 2.971 mmol) were 
dissolved in dimethyl formamide (DMF) (25 mL) under a nitrogen 
atmosphere. 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) (1.11 
mL, 6.37 mmol) and diisopropylethylamine (DIPEA) (2.21 mL, 12.73 
mmol)) were added and the reaction stirred at room temperature for 60 
hours.  The solvent was removed under reduced pressure and redissolved 
in CHCl3 (30 mL). The organic layer was washed with water (10 mL), 
saturated brine (10 mL) and water (10 mL). The solution was dried over 
anhydrous MgSO4 and the solvent removed under reduced pressure. The 
crude solid was purified by column chromatography (5 : 1 CHCl3 : isopropyl 
alcohol) to give the title compound as a white solid.  
Yield: 
0.877 g, 55 % 
m/z (ESI) 
503.2306 ([C25H31FN4O6+H]+ calculated mass 503.2300, -1.0 ppm mean 
error)  
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1H NMR: (400 MHz, CDCl3, δH (ppm)): 
8.56 (s, 1H, H-11, CH), 8.08 (d, 3JF-H = 13.3 Hz, 1H, H-3, CH), 7.27 (d, 4JF-H = 
7.8 Hz, H-17, CH), 4.04 (d, 3JH-H = 4.6 Hz, H-27, CH2),  3.92 (s, 3H, H-25, 
CH3), 3.87 (t, 3JH-H = 4.6 Hz, 2H, H-21, H-23, piperazine, CH2), 3.63 (t, 3JH-H = 
4.6 Hz, 2H, H-21, H-23, piperazine, CH2), 3.45-3.40 (m, 1H, H-13, 
cyclopropane, CH), 3.28-3.23 (m, 4H, H-20, H-24, CH2), 1.46 (s, 9H, H-34, 
H-35, H-36, Boc group, CH3), 1.36-1.31 (m, 2H, cyclopropane, CH2), 1.17-
1.13 (m, 2H, cyclopropane, CH2) 
13C NMR: (100 MHz, CDCl3, δC (ppm)): 
172.9 (s, C-5), 169.2 (s, C-30), 167.0 (s, C-26), 166.3 (s, C-8), 153.3 (d, 1JC-F = 
249.2 Hz, C-2) 148.5 (s, C-11), 143.8 (d, 2JC-F = 10.5 Hz, C-18),  137.9 (d, 5JC-H 
= 1.9 Hz, C-7), 123.6 (d, 3JC-F = 6.7 Hz, C-4), 113.5 (d, 2JC-F = 23.0 Hz, C-3), 
110.1 (s, C-16), 105.2 (d, 3JC-F = 2.9 Hz, C-17), 79.8 (s, C-33), 52.1 (s, C-25), 
50.0 (s, C-20, C-21, C-23, C-24), 49.63 (s, C-20, C-21, C-23, C-24), 44.3 (s, C-
20, C-21, C-23, C-24), 42.2 (s, C-20, C-21, C-23, C-24), 41.7 (s, C-27), 34.5 (s, 
C-13), 28.3 (s, C-34, C-35, C-36), 8.1 (s, C-14, C-15) 
19F NMR: (376 MHz, CDCl3, δF (ppm)): 
-123.84 (dd, 3JH-F = 13.0 Hz, 4JF-H = 5.8 Hz, F-1)  
IR: (cm-1) 
3418 (C-H), 2978 (C-H), 1720 (C=O, C-8, O-9), 1617 (C=O, C-5, O-6), 
Melting Point: (°C) 
180.5-183.1 
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4.2.1.3 2-(4-(1-cyclopropyl-6-fluoro-3-(methoxycarbonyl)-4-oxo-1,4-
dihydroquinolin-7-yl)piperazin-1-yl)-2-oxoethan-1-aminium 2,2,2-
trifluoroacetate, 57 
 
Chemical Formula: C22H24F4N4O6 
Molecular Weight: 516.4496 gmol-1 
Compound 56 (0.429 g, 0.854 mmol) was taken up in DCM (20 mL) and 
TFA (4 mL) was added. The solution was stirred overnight and 
concentrated under reduced pressure to give a yellow oil. This was 
suspended in EtOH (10 mL) and the solvent removed under reduced 
pressure. This was resuspended in EtOH (10ml) and solvent removed 8 
times to give the title compound as an off-white solid.  
Yield: 
0.434 g, 98 % 
m/z (ESI) 
403.1776 ([C20H24FN4O4+H]+ calculated mass 403.1776, -1.0 ppm mean 
error)  
1H NMR: (400 MHz, d6-DMSO, δH (ppm)): 
8.45 (s, 1H, H-11, CH), 8.12 (s, broad, N-29), 7.77 (d, 3JF-H = 13.3 Hz, 1H, H-
3, CH), 7.44 (d, 4JF-H = 7.3 Hz, H-17, CH), 3.97 (s, H-27, CH2),  3.73 (s, 3H, H-
25, CH3) 3.61 (t, 3JH-H = 6.4 Hz, 2H, H-21, H-23, piperazine, CH2), 3.64 (q, 
3JH-H = 3.7, 1H, H-13, cyclopropane, CH) 3.29 (t, 3JH-H = 4.6 Hz, 2H, H-20, H-
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24, piperazine, CH2), 3.25 (t, 3JH-H = 5.0 Hz  2H, H-20, H-24, piperazine, 
CH2) 1.27-1.11 (m, 4H, cyclopropane, CH2),  
13C NMR: (100 MHz, d6-DMSO, δC (ppm)): 
171.6 (d, 4JF-C = 1.9 Hz, C-5), 165.5 (s, C-26), 165.0 (s, C-8), 152.6 (d, 1JF-C = 
152.7 Hz, C-2), 148.4 (s, C-11), 143.5 (d, 2JF-C = 10.5 Hz, C-18), 138.0 (s, C-
7), 122.2 (d, 3JF-C = 6.7 Hz, C-4), 111.7 (d, 2JF-C = 23 Hz, C-3), 109.0 (s, C-16), 
106.7 (d, 3JF-C = 2.9 Hz, C-17), 51.3 (s, C-25), 49.4 (q, 1JF-C = 13.4 Hz, C-33), 
43.9 (s, C-20, C-21, C-23, C-24), 41.3(s, C-20, C-21, C-23, C-24), 36.0 (s, C-
20, C-21, C-23, C-24), 34.8 (s, C-13), 33.6 (s, C-20, C-21, C-23, C-24), 7.6 (s, 
C-14, C-15) 
19F NMR: (376 MHz, d6-DMSO, δF (ppm)): 
-73.46 (s, 3F, F-34, F-35, F-36, TFA salt, CF3) -124.48 - -124.43 (m, 1F, F-1) 
IR: (cm-1) 
3096 (C-H), 1711 (C=O, C-8, O-9), 1651 (C=O, C-5, O-6), 
Melting Point: (°C) 
Unable to be determined within the range of the instrument 
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4.2.1.4 Methyl 1-cyclopropyl-6-fluoro-4-oxo-7-(4-
((phenylcarbamothioyl)glycyl)piperazin-1-yl)-1,4-dihydroquinoline-3-
carboxylate, 58
 
Chemical Formula: C27H28FN5O4S 
Molecular Weight: 537.61 gmol-1 
Compound 57 (0.32 g, 0.619 mmol) was dissolved in MeCN (20 mL). Et3N 
(0.13 mL, 0.931 mmol) was added followed by phenyl isothiocyanate 
(0.08mL g, 0.682 mmol). The solution was stirred under nitrogen at room 
temperature for 24 hours. The mixture was cooled in ice and filtered to 
give the title compound as white crystals.  
Yield: 
0.177g, 53% 
m/z (ESI) 
538.1910 ([C27H28FN5O4S +H]+ calculated mass 538.1919, 2.5 ppm mean 
error)  
1H NMR: (400 MHz, d6-DMSO, δH (ppm)): 
10.02 (s, 1H, broad, H-31, NH) 8.44 (s, 1H, H-11, CH), 7.83 (s, 1H, broad, H-
29, NH), 7.77 (d, 3JF-H = 13.3 Hz, 1H, H-3, CH), 7.51 (d, 3JH-H = 7.3 Hz, 2H, H-
34, H-38), 7.46 (d, 4JF-H = 7.3 Hz, 1H, H-17), 7.34 (t 3JH-H = 7.8 Hz, H-35, H-37 
CH), 7.12 (t, 3JH-H = 7.3 Hz, 1H, H-36), 4.45 (d, 3JH-H = 3.7 Hz, 2H, H-27), 3.73 
(s, 3H, H-25, CH3) 3.62-3.70 (m, 4H, H-21, H-23, piperazine, CH2), 3.35-3.30 
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(m, H-20, H-24, piperazine, CH2, H-13, cyclopropane, CH, under water 
peak), 3.27-3.23 (m, 2H, H-13, piperazine, H-20, H-24, CH2) 3.29 (t, 3HH-H = 
5 Hz, 2H, H-20, H-24) 3.23 (t, 3HH-H = 5 Hz, 2H, H-20, H-24) 1.23-1.28 (m, 
2H, H-14, H-15, cyclopropane,  CH2), 1.10-1.11 (m, 2H, H-14, H-15, 
cyclopropane, CH2) 
13C NMR: (100 MHz, d6-DMSO, δC (ppm)): 
179.9 (s C-5), 171.6 (s, C-30), 166.6 (s, C-8), 165.0 (s, C-26), 153.3 (d, 1JC-F = 
248.3 Hz, C-2) 148.4 (s, C-11), 143.6 (d, 2JC-F = 10.5 Hz, C-18), 139.2 (s, C-
33)  138.0 (s, C-7), 128.7 (s, C-35, C-37), 124.3 (s, C-36), 122.8 (s, C-38, C-
34), 122.1 (d, 3JC-F = 6.7 Hz, C-4), 111.5 (d, 2JC-F = 23.0 Hz, C-3), 109.0 (s, C-
16), 106.6 (d, 3JC-F = 1.9 Hz, C-17), 51.3 (s, C-25), 49.6 (s, C-20, C-21, C-23, 
C-24), 49.5 (s, C-20, C-21, C-23, C-24), 45.8 (s, C-27), 43.8 (s, C-20, C-21, C-
23, C-24), 43.8 (s, C-20, C-21, C-23, C-24),   34.8 (s, C-13), 8.0 (s, C-14, C-15) 
19F NMR: (376 MHz, d6-DMSO, δF (ppm)): 
-124.48 - -124.43 (m, 1F, F-1) 
IR: (cm-1) 
3409 (N-H, N-29, N-31), 2977 (C-H), 1721 (C=O, C-8, O-9),  1657 (C=O, C-5, 
O-6), 
Melting point: (°C) 
160.9-163.0 
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4.2.1.5 1-cyclopropyl-6-fluoro-4-oxo-7-(4-
((phenylcarbamothioyl)glycyl)piperazin-1-yl)-1,4-dihydroquinoline-3-
carboxylic acid, 62 
 
Chemical Formula: C26H26FN5O4S 
Molecular Weight: 523.58 
Compound 58 (0.39 2g, 0.727 mmol) was dissolved in DMF (25 mL) and 
NaOH (0.05 g, 1.25 mmol) was added. The solution was stirred overnight 
at room temperature. The solvent was removed under reduced pressure 
and the residue dissolved in water (20 mL) The pH was adjusted to 1 using 
HCl (6 M, aq, dropwise) and the suspension was filtered to give the title 
compound as pale yellow crystals.  
Yield: 
0.198 g, 52 % 
m/z (ESI) 
524.1772 ([C26H26FN5O4S +H]+ calculated mass 524.1762, 1.7 ppm mean 
error)  
1H NMR: (400 MHz, d6-DMSO, δH (ppm)): 
9.95 (s, 1H, broad, H-31, NH) 8.87 (s, 1H, H-11, CH), 7.80 (s, 1H, broad, H-
28, NH), 7.93 (d, 3JF-H = 13.3 Hz, 1H, H-3, CH), 7.59 (d, 3JH-H = 7.3 Hz, 2H, H-
33, H-37, CH), 7.51 (d, 4JF-H = 8.2 Hz, 1H, H-17, CH), 7.34 (t 3JH-H = 7.3 Hz, H-
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34, H-36, CH), 7.12 (t, 3JH-H = 7.3 Hz, 1H, H-35), 4.46 (d, 3JH-H = 4.1 Hz, 2H, 
H-27), 3.82 (s, 1H, H-13, cyclopropane), 3.74 (s, broad, 2H, H-21, H-23, 
piperazine), 3.69 (s, broad, 2H, H-21, H-23, piperazine), 3.43 (s, broad, 2H, 
H-20, H-24, piperazine), 3.38 (s, broad, 2H, H-20, H-24, piperazine),   1.33-
1.34 (m, 2H, H-14, H-15, cyclopropane,  CH2), 1.19 (m, 2H, H-14, H-15, 
cyclopropane, CH2) 
13C NMR: (100 MHz, d6-DMSO, δC (ppm)): 
180.00 (s C-5), 176.28 (s, C-30), 166.62 (s, C-8), 165.71 (s, C-25), 152.79 (d, 
1JC-F = 249.2 Hz, C-2) 147.89 (s, C-11), 144.68 (d, 2JC-F = 10.5 Hz, C-18), 
139.14 (s, C-7)  139.04 (s, C-32), 128.53 (s, C-33, C-37), 124.78 (s, C-35), 
122.78 (s, C-36, C-34), 118.75 (d, 3JC-F = 8.6 Hz, C-4), 110.95 (d, 2JC-F = 23.0 
Hz, C-3), 106.76 (s, C-16), 106.45 (s, C-17), 41.00-49.42 (m, C-20, C-21, C-
23, C-24), 45.64 (s, C-27), 35.73 (s, C-13), 7.46 (s, C-14, C-15) 
19F NMR: (376 MHz, d6-DMSO, δF (ppm)): 
-121.71 - -121.76 (m, F-1) 
IR: (cm-1) 
3301 (N-H, N-29, N-31) 3070, 2830 (C-H) 1713 (C=O, C-8, O-9), 1651 (C=O, 
C-5, O-6), 
Melting point: (°C) 
Unable to be determined within the range of the instrument 
Elemental analysis 
Calculated for C26H26FN5O4S . 0.45H2O: %C 58.73 %H 5.10 %N 13.17 
Observed for C26H26FN5O4S . 0.45H2O %C 58.59 %H 4.98 %N 13.08 
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4.2.1.6 Methyl 7-(4-(((3-chloro-4-
fluorophenyl)carbamothioyl)glycyl)piperazin-1-yl)-1-cyclopropyl-6-
fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate, 59
 
Chemical Formula: C27H26ClF2N5O4S 
Molecular Weight: 590.04 gmol-1 
Compound 57 (0.100 g, 0.193 mmol) was dissolved in MeCN (20 mL). Et3N 
(0.107 mL, 0.767 mmol) was added followed by 3-chloro-4-fluorophenyl 
isothiocyanate (0.053 g, 0.282 mmol). The solution was stirred under 
nitrogen at room temperature for 24 hours. The mixture was cooled in ice 
and filtered to give the title compound as white crystals. 
Yield: 
0.097 g, 84 % 
m/z (ESI) 
590.1442 ([C27H2635ClF2N5O4S +H]+ calculated mass 590.1435, 1.0 ppm 
mean error)  
1H NMR: (400 MHz, d6-DMSO, δH (ppm)): 
10.15 (s, 1H, broad, H-31, NH) 8.43 (s, 1H, H-11, CH), 8.01 (s, 1H, broad, H-
29, NH), 7.93 (d, 1H, 3JH-H = 6 Hz, H-35), 7.76 (d, 3JF-H = 13.3 Hz, 1H, H-3, 
CH), 7.45 (d, 4JF-H = 7.3 Hz, 1H, H-17), 7.39-7.37 (m, 2H, H-38, H34), 4.44 (d, 
3JH-H = 3.7 Hz, H-27, CH2), 3.73-3.62 (m, 8H, H-13, cyclopropane, H-21, H-
23, piperazine H-25, CH3) 3.29-3.25 (m, 4H, H-20, H-24, piperazine, CH2), 
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1.27-1.23 (m, 2H, H-14, H-15, cyclopropane,  CH2), 1.11-1.10 (m, 2H, H-14, 
H-15, cyclopropane, CH2) 
13C NMR: (100 MHz, d6-DMSO, δC (ppm)): 
180.3 (s C-5), 171.5 (s, C-30), 166.5 (s, C-8), 164.6 (s, C-26), 160.7 (d, 1JF-C = 
220.5 Hz, C-36), 152.6 (d, 1JC-F = 247.3 Hz, C-2) 148.4 (s, C-11), 143.5 (d, 2JC-
F = 10.5 Hz, C-18) 138.0 (s, C-7), 124.4 (s, C-34), 124.4 (d, 3JF-C = 1.9 Hz, C-
38), 124.3 (s, C-33), 122.7 (d, 3JC-F = 6.7 Hz, C-4), 118.8 (d, 2JC-F = 18.2 Hz, C-
37), 116.7 (d, 2JC-F = 22, C-35), 111.6 (d, 2JC-F = 22.0 Hz, C-3), 109.0 (s, C-16), 
106.6 (d, 3JC-F = 1.9 Hz, C-17), 51.3 (s, C-25), 49.4 (s, C-20, C-21, C-23, C-24), 
49.4 (s, C-20, C-21, C-23, C-24), 45.8 (s, C-27), 43.8 (s, C-20, C-21, C-23, C-
24), 41.2 (s, C-20, C-21, C-23, C-24),   34.8 (s, C-13), 7.6 (s, C-14, C-15) 
19F NMR: (376 MHz, d6-DMSO, δF (ppm)): 
-122.0 (d, 3JH-F = 5.8 Hz, F-40), -124.4 - -124.47 (m, F-1) 
IR: (cm-1) 
3293 (N-H, N-29, N-31), 3074 (C-H) 1718 (C=O, C-8, O-9), 1660 (C=O, C-5, 
O-6), 
Melting point: (°C) 
Unable to be determined within the range of the instrument 
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4.2.1.7 7-(4-(((3-chloro-4-fluorophenyl)carbamothioyl)glycyl)piperazin-1-
yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid, 
63
 
Chemical Formula: C26H24F2ClN5O4S 
Molecular Weight: 576.02 
Compound 59 (0.097 g, 0.164 mmol) was dissolved in DMF (25mL) and 
NaOH (0.05 g, 1.25 mmol) was added. The solution was stirred overnight 
at room temperature. The solvent was removed under reduced pressure 
and the residue dissolved in water (20 mL) The pH was adjusted to 1 using 
HCl (6 M, aq, dropwise) and the suspension was filtered to give the title 
compound as pale-yellow crystals. 
Yield: 
0.046 g, 49 % 
m/z (ESI) 
576.1280 ([C26H2435Cl F2N5O4S +H]+ calculated mass 576.1278, 0.5 ppm 
mean error)  
1H NMR: (400 MHz, d6-DMSO, δH (ppm)): 
10.18 (s, 1H, broad, H-31, NH) 8.65 (s, 1H, H-11, CH), 8.04 (s, 1H, broad, H-
28, NH), 7.91 (d, 3JF-H = 13.3 Hz, 1H, H-3, CH), 7.38 (d, 4JF-H = 8.2 Hz, 1H, H-
17), 7.94 (s, 1H, C-39, CH2), 7.93 (d, 1H, 3JH-H = 6.4 Hz, H-33), 7.39-7.37 (m, 
1H, H34), 4.45 (d, 3JH-H = 2.7 Hz, H-27, CH2), 3.82 (s, broad, 1H, H-13, 
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cyclopropane), 3.74 (H-23, H-21, piperazine, CH2) 3.68 (s, broad, H-23, H-
21, piperazine, CH2), 3.42 (s, broad, H-20, H-24, piperazine, CH2), 3.34 (s, 
broad, H-20, H-24, piperazine, CH2), 1.32-1.33 (m, 2H, H-14, H-15, 
cyclopropane,  CH2), 1.19 (s, 2H, H-14, H-15, cyclopropane, CH2) 
13C NMR: (100 MHz, d6-DMSO, δC (ppm)): 
180.3 (s C-5), 176.4 (s, C-29), 166.6 (s, C-8), 164.9 (s, C-25), 155.0 (d, 1JC-F = 
329.7 Hz, C-35), 152.9 (d, 1JF-C = 248.3 Hz, C-2), 148.1 (s, C-11), 144.8 (d, 
2JC-F = 9.6 Hz, C-18) 139.1 (s, C-7), 124.2 (s, C-32), 123.2-123.1 (m, C-33, C-
39), 122.7 (d, 3JC-F = 6.7 Hz, C-4), 118.8 (d, 2JC-F = 10.5 Hz, C-37), 116.6 (d, 
2JC-F = 21.1, C-34), 111.2 (d, 2JC-F = 23.0 Hz, C-3), 106.8 (s, C-16), 106.6 (d, 
3JC-F = 2.9 Hz, C-17), 49.4-49.1 (m, C-20, C-21, C-23, C-24), 45.8 (s, C-27), 
43.7 (s, C-20, C-21, C-23, C-24), 41.2 (s, C-20, C-21, C-23, C-24),   35.9 (s, C-
13), 7.3 (s, C-14, C-15) 
19F NMR: (376 MHz, d6-DMSO, δF (ppm)): 
-122.0 - -122.01 (d, 3JH-F = 5.8 Hz, F-40), -121.66 - -121.61 (m, F-1) 
IR: (cm-1) 
3304 (N-H, N-29, N-31), 3062 (C-H) 1711 (C=O, C-8, O-9),  1625 (C=O, C-5, 
O-6) 
Melting point: (°C) 
153.5-158.9 
Elemental analysis 
Calculated for C26H26FN5O4S . 1.00 H2O: %C 52.57 %H 4.41 %N 11.79 
Observed for C26H26FN5O4S . 1.00 H2O %C 52.29 %H 4.11 %N 11.69 
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4.2.1.8 Methyl 7-(4-(((3-chlorophenyl)carbamothioyl)glycyl)piperazin-1-
yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate, 60 
 
Chemical Formula: C27H27ClFN5O4S 
Molecular Weight: 572.05 gmol-1 
Compound 57 (0.15 g, 0.291 mmol) was dissolved in MeCN (20 mL). Et3N 
(0.162 mL, 1.15 mmol) was added followed by 3-chlorophenyl 
isothiocyanate (0.076 mL, 0.579 mmol). The solution was stirred under 
nitrogen at room temperature for 24 hours. The mixture was cooled in ice 
and filtered to give the title compound as white crystals. 
Yield: 
0.144 g, 87 % 
m/z (ESI) 
572.1538 ([C27H27ClFN5O4S +H]+ calculated mass 572.1529, 1.7 ppm mean 
error)  
1H NMR: (400 MHz, d6-DMSO, δH (ppm)): 
10.20 (s, 1H, broad, H-31, NH) 8.43 (s, 1H, H-11, CH), 8.05 (s, 1H, broad, H-
29, NH), 7.88 (s, 1H H-38), 7.75 (d, 3JF-H = 13.3 Hz, 1H, H-3, CH), 7.45 (d, 4JF-
H = 7.3 Hz, 1H, H-17), 7.40-7.32 (m, 2H, H-34, H-35, H-36), 7.14 (d, 3JH-H = 
7.3 Hz, H-34, H-35, H-36), 4.45 (d, 3JH-H = 3.7 Hz, H-27, CH2), 3.73 (s, 3H, H-
25, CH3), 3.76-3.60 (m, 5H, H-13, cyclopropane, H-23, H-21, piperazine), 
3.32 (s, broad, 2H, H-20, H-24, piperazine, CH2), 3.25 (s, broad, 2H, H-20, 
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H-24, piperazine, CH2), 1.23-1.30 (m, 2H, H-14, H-15, cyclopropane,  CH2), 
1.11 (s, broad, 2H, H-14, H-15, cyclopropane, CH2) 
13C NMR: (100 MHz, d6-DMSO, δC (ppm)): 
179.9 (s C-5), 171.5 (s, C-30), 166.5 (s, C-8), 164.9 (s, C-26), 152.6 (d, 1JC-F = 
249.2 Hz, C-2) 148.3 (s, C-11), 143.5 (d, 2JC-F = 10.5 Hz, C-18), 141.1 (s, C-
37), 138.2 (s, C-7), 132.7 (s, C-33), 130.0 (s, C-34, C-35, C-36), 123.5 (s, C-
34, C-35, C-36), 121.6 (s, C-38), 122.7 (d, 3JC-F = 6.7 Hz, C-4), 120.6 (s, C-34, 
C-35, C-36), 111.6 (d, 2JC-F = 23.0 Hz, C-3), 108.9 (s, C-16), 106.6 (d, 3JC-F = 
1.9 Hz, C-17), 51.3 (s, C-25), 49.6 (s, C-20, C-21, C-23, C-24), 49.5 (s, C-20, 
C-21, C-23, C-24), 45.8 (s, C-27), 43.8 (s, C-20, C-21, C-23, C-24), 41.3 (s, C-
20, C-21, C-23, C-24),   34.8 (s, C-13), 7.6 (s, C-14, C-15) 
19F NMR: (376 MHz, d6-DMSO, δF (ppm)): 
-124.41 - -124.47 (m, F-1) 
IR: (cm-1) 
3281 (N-H, N-29, N-31), 3055 (C-H) 1725 (C=O, C-8, O-9), 1655 (C=O, C-5, 
O-6), 
Melting point: (°C) 
Unable to be determined within the range of the instrument 
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4.2.1.9 7-(4-(((3-Chlorophenyl)carbamothioyl)glycyl)piperazin-1-yl)-1-
cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid, 64 
 
 Chemical Formula: C26H25FClN5O4S 
Molecular Weight: 558.03 
Compound 60 (0.144 g, 0.251 mmol) was dissolved in DMF (25 mL) and 
NaOH (0.05 g, 1.25 mmol) was added. The solution was stirred overnight 
at room temperature. The solvent was removed in vacuo and the residue 
dissolved in water (20 mL) The pH was adjusted to 1 using HCl (6 M, aq, 
dropwise) and the suspension was filtered to give the title compound as 
pale-yellow crystals.  
Yield: 
0.105 g, 75 % 
m/z (ESI) 
558.1363 ([C26H25F35ClN5O4S +H]+ calculated mass 558.1373, 1.8 ppm 
mean error)  
1H NMR: (400 MHz, d6-DMSO, δH (ppm)): 
10.28 (s, 1H, broad, H-30, NH) 8.66 (s, 1H, H-11, CH), 8.11 (s, 1H, broad, H-
28, NH), 7.88 (s, 1H H-37), 7.92 (d, 3JF-H = 13.3 Hz, 1H, H-3, CH), 7.58 (s, 1H, 
H-34, H-35, H-36), 7.40-7.31 (m, 2H, H-33, H-34, H-35), 7.14 (d, 3JH-H = 7.3 
Hz, H-17), 4.46 (d, 3JH-H = 3.7 Hz, H-27, CH2), 3.83 (s, broad, 1H, H-13, 
cyclopropane, CH), 3.75 (s, 2H, H-21, H-23, piperazine), 3.68 (s, 2H, H-21, 
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H-23, piperazine), 3.42 (s, broad, 2H, H-20, H-24, piperazine, CH2), 3.35 
(under water peak, H-20, H-24, piperazine, CH2), 1.32 (s, broad, 2H, H-14, 
H-15, cyclopropane,  CH2), 1.19 (s, broad, 2H, H-14, H-15, cyclopropane, 
CH2) 
13C NMR: (100 MHz, d6-DMSO, δC (ppm)):  
179.9 (s C-5), 176.4 (s, C-29), 166.6 (s, C-8), 165. (s, C-25), 152.93 (d, 1JC-F = 
250.2 Hz, C-2) 148.1 (s, C-11), 144.9 (d, 2JC-F = 6.7 Hz, C-18), 141.1 (s, C-36), 
139.1 (s, C-32)  132.7 (s, C-7), 130.2 (s, C-33, C-34, C-35), 123.5 (d, 3JC-F = 
2.9 Hz, C-4) 121.6 (s, C-33, C-34, C-35), 121.6 (s, C-37), 111.0 (d, 2JC-F = 23.0 
Hz, C-3), 106.8 (s, C-16), 106.6 (d, 3JH-H = 1.9 Hz, C-17), 49.3 (s, C-20, C-21, 
C-23, C-24), 49.2 (s, C-20, C-21, C-23, C-24), 45.7 (s, C-27), 43.7 (s, C-20, C-
21, C-23, C-24), 41.1 (s, C-20, C-21, C-23, C-24), 39.9 (s, C-13), 7.6 (s, C-14, 
C-15) 
19F NMR: (376 MHz, d6-DMSO, δF (ppm)): 
-121.62  -121.68 (m, F-1) 
IR: (cm-1) 
3302 (N-H, N-28, N-31) 3070, 2926 (C-H) 1713 (COOH), 1626 (C=O, C-5, O-
6) 
Melting point: (°C) 
204.6-207.5 
Elemental analysis 
Calculated for C26H26FN5O4S . 0.6HCl . 0.1NaCl: %C 53.31 %H 4.41 %N 
11.96 
Observed for C26H26FN5O4S . 0.6HCl . 0.1NaCl %C 53.29 %H 4.35 %N 11.90 
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4.2.1.10 Methyl 7-(4-(((4-chlorophenyl)carbamothioyl)glycyl)piperazin-1-
yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate, 61 
 
Chemical Formula: C27H27ClFN5O4S 
Molecular Weight: 572.05 gmol-1 
Compound 57 (0.15 g, 0.291 mmol) was dissolved in MeCN (20 mL). Et3N 
(0.162 mL, 1.15 mmol) was added followed by 3-chlorophenyl 
isothiocyanate (0.076 mL, 0.579 mmol). The solution was stirred under 
nitrogen at room temperature for 24 hours. The mixture was cooled in ice 
and filtered to give the title compound as white crystals.  
Yield: 
0.135 g, 81% 
m/z (ESI) 
572.1539 ([C27H2735ClFN5O4S+H]+ calculated mass 572.1529, 1.9 ppm mean 
error)  
1H NMR: (400 MHz, d6-DMSO, δH (ppm)): 
10.13 (s, 1H, broad, H-31, NH) 8.43 (s, 1H, H-11, CH), 7.96 (s, 1H, broad, H-
29, NH), 7.76 (d, 3JF-H = 13.3 Hz, 1H, H-3, CH), 7.58 (d, 3JH-H = 8.7 Hz, 2H, H-
34, H-38), 7.45 (d, 4JF-H = 7.3 Hz, 1H, H-17), 7.37 (d, 3JH-H = 8.7 Hz, 2H, H-35, 
H-37), 4.45 (s, H-27, CH2), 3.73 (s, 3H, H-25, CH3), 3.80-3.65 (m, 5H, H-13, 
cyclopropane, H-23, H-21, piperazine), 3.32 (s, broad, 2H, H-20, H-24, 
piperazine, CH2), 3.25 (s, broad, 2H, H-20, H-24, piperazine, CH2), 1.27-
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1.25 (m, 2H, H-14, H-15, cyclopropane,  CH2), 1.10 (s, broad, 2H, H-14, H-
15, cyclopropane, CH2) 
13C NMR: (100 MHz, d6-DMSO, δC (ppm)): 
180.0 (s C-5), 171.5 (s, C-30), 166.5 (s, C-8), 164.9 (s, C-26), 155.3 (d, 1JC-F = 
247.3 Hz, C-2) 148.4 (s, C-11), 143.5 (d, 2JC-F = 10.5 Hz, C-18), 138.4 (s, C-
33)  138.0 (s, C-7), 128.4 (s, C-35, C-37), 127.8 (s, C-36), 124.1 (s, C-38, C-
34), 122.1 (d, 3JC-F = 6.7 Hz, C-4), 111.6 (d, 2JC-F = 23.0 Hz, C-3), 109.0 (s, C-
16), 106.6 (d, 3JC-F = 2.9 Hz, C-17), 51.3 (s, C-25), 49.6-49.3 (m, C-20, C-21, 
C-23, C-24), 45.7 (s, C-27), 43.8 (s, C-20, C-21, C-23, C-24), 41.2 (s, C-20, C-
21, C-23, C-24), 34.8 (s, C-13), 7.6 (s, C-14, C-15) 
19F NMR: (376 MHz, d6-DMSO, δF (ppm)): 
-124.42 - -124.47 (m, F-1) 
IR: (cm-1) 
3279 (N-H, N-29, N-31), 2981 (C-H), 1724 (COOH), 1656 (C=O, C-5, O-6) 
Melting point: (°C) 
Unable to be determined within the range of the instrument 
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4.2.1.11 7-(4-(((4-Chlorophenyl)carbamothioyl)glycyl)piperazin-1-yl)-1-
cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid, 65 
 
Chemical Formula: C26H25FClN5O4S 
Molecular Weight: 558.03 
Compound 61 (0.135 g, 0.236 mmol) was dissolved in DMF (25 mL) and 
NaOH (0.05 g, 1.25 mmol) was added. The solution was stirred overnight 
at room temperature. The solvent was removed under reduced pressure 
and the residue dissolved in water (20 mL) The pH was adjusted to 1 using 
HCl (6 M, aq,  dropwise) and the suspension was filtered to give the title 
compound as pale yellow crystals. 
Yield: 
0.053 g, 40 % 
m/z (ESI) 
558.1381 ([C26H2535ClFN5O4S +H]+ calculated mass 558.1373, 1.1 ppm 
mean error)  
1H NMR: (500 MHz, d6-DMSO, δH (ppm)): 
10.17 (s, 1H, broad, H-31, NH) 8.66 (s, 1H, H-11, CH), 7.98 (s, 1H, broad, H-
28, NH), 7.93 (d, 3JF-H = 12.8 Hz, 1H, H-3, CH), 7.58 (d, 3JH-H = 8.7 Hz, 2H, H-
33, H-37), 7.37 (d, 3JH-H = 8.7 Hz, 3H, H-17, H-35, H-37), 4.45 (d, 3JH-H = 4 Hz, 
H-27, CH2), 3.82 (s, broad, 1H, H-13, cyclopropane), 3.74 (s, 2H, H-21, H-
23, piperazine), 3.68 (s, 2H, H-21, H-23, piperazine), 3.42 (s, 2H, H-20, H-
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24, piperazine, CH2), 3.34 (s, 2H, H-20, H-24, piperazine, CH2), 1.33-1.32 
(m, 2H, H-14, H-15, cyclopropane,  CH2), 1.19 (s, broad, 2H, H-14, H-15, 
cyclopropane, CH2) 
13C NMR: (125 MHz, d6-DMSO, δC (ppm)): 
180.1 (s C-5), 176.3 (s, C-8), 166.6 (s, C-29), 165.8 (s, C-25), 152.9 (d, 1JC-F = 
246.5 Hz, C-2) 148.0 (s, C-11), 144.8 (d, 2JC-F = 10.1 Hz, C-18), 138.4 (s, C-
32)  139.1 (s, C-7), 128.4 (s, C-34, C-36), 127.7 (s, C-36), 124.0 (s, C-33, C-
37), 118.8 (d, 3JC-F = 7.3 Hz, C-4), 111.0 (d, 2JC-F = 22.0 Hz, C-3), 106.8 (s, C-
16), 106.6 (s, C-17), 49.3 (s, C-20, C-21, C-23, C-24), 49.1 (s, C-20, C-21, C-
23, C-24), 45.7 (s, C-27), 43.7 (s, C-20, C-21, C-23, C-24), 41.1 (s, C-20, C-21, 
C-23, C-24), 35.8 (s, C-13), 7.6 (s, C-14, C-15) 
19F NMR: (376 MHz, d6-DMSO, δF (ppm)): 
-124.62 - -124.67 (m, F-1) 
IR: (cm-1) 
3299 (N-H, N-28, N-31) 3095, 2976 (C-H) 1722 (COOH) 1627 (C=O, C-5, O-
6) 
Melting point: (°C) 
185.4-189.1 
Elemental analysis 
Calculated for C26H26FN5O4S . 0.8HCl . 0.1NaCl: %C 52.66 %H 4.39 %N 
11.67 
Observed for C26H26FN5O4S . 0.6HCl . 0.1NaCl %C 53.81 %H 4.25 %N 11.67 
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4.2.2 Synthesis of a Ciprofloxacin Disulfide-linked Dimer 
 
4.2.2.1 7-(4-(tert-Butoxycarbonyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-
4-oxo-1,4-dihydroquinoline-3-carboxylic acid, 67
 
Molecular Formula: C22H26FN3O5 
Molecular weight: 431.46 gmol-1 
Ciprofloxacin (2.20 g, 6.63 mmol) was dissolved in water (10 mL) and 1,4-
dioxane (10 mL). NaOH (1 M, aq, 10 mL) was added and the mixture 
stirred at RT for 1 hour. Di-tert-butyl dicarbonate (2.08 g, 9.53 mmol) was 
dissolved in 1,4-dioxane (4 mL) and added. The reaction was stirred at RT 
for 24 hours. The solvent was reduced to 15% w/v under reduced pressure 
and acetone (40 mL) was added. The suspension was filtered and washed 
with cold acetone (3 x 10 mL) to give the title compound as a white solid, 
Compound 6. 
Yield: 
2.22 g, 99 %  
m/z (ESI) 
432.1923 [C22H26FN3O5+H]+ (calculated 432.1929, 2.3 ppm mean error) 
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1H NMR: (400 MHz, CDCl3, δH (ppm)): 
8.73 (s, 1H, H-11, CH), 7.99 (d, 3JF-H = 12.8 Hz, 1H, H-3, CH), 7.36 (d, 4JF-H = 
7.3 Hz, H-17, CH), 3.66-3.38 (m, 4H, H-21, H-23, piperazine, CH2) 3.56-3.53 
(m, 1H, H-13  cyclopropane, CH), 3.31-3.28 (m, 4H, H-20, H-24 piperazine, 
CH2), 1.50 (s, 9H, H-31, H-32, H-33, Boc group) ,1.42-1.38 (m, 2H, 
cyclopropane, CH2), 1.18-1.23 (m, 2H, cyclopropane, CH2) 
13C NMR: (100 MHz, CDCl3, δC (ppm)): 
177.0 (d, 4JF-C = 2.9 Hz, C-5), 170.4 (s, C-8), 166.9 (s, C-26), 153.4 (d, 1JF-C = 
218.5 Hz, C-2), 147.5 (s, C-11), 145.8 (d, 2JF-C = 10.5 Hz, C-18), 139.0 (s, C-
7), 120.0 (d, 3JC-F = 7.7 Hz, C-4), 112.4 (d, 2JF-C = 26.0 Hz, C-3), 108.1 (s, C-
16), 105.0 (d, 3JF-C = 2.9 Hz, C-17), 80.3 (s, C-30), 67.1 (s, C-20, C-22, C-23, 
C-24), 49.7 (s, C-20, C-22, C-23, C-24), 49.7 (s, C-20, C-22, C-23, C-24), 35.3 
(s, C-13), 28.4 (s, C-31, C-32, C-33), 8.2 (s, C-14, C-15) 
19F NMR: (376 MHz, CDCl3, δF (ppm)): 
-120.84 - -120.89 (m, F-1) 
IR: (cm-1) 
2969 (C-H) 1731 (COOH) 1688 (C=O, C-5, O-6) 
Melting point: (°C) 
Unable to be determined within the range of the instrument 
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4.2.2.2 Disulfanediylbis(ethane-2,1-diyl) bis(7-(4-(tert-
butoxycarbonyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-
dihydroquinoline-3-carboxylate), 68 
 
Chemical Formula: C48H58F2N6O10S2 
Molecular Weight: 981.14 gmol-1 
Compound 67 (0.32 g, 0.714 mmol), HATU (0.60 g, 1.577 mmol) and 
DIPEA (0.26 g, 2.01 mmol) were dissolved in CHCl3 (10 mL) and heated to 
40 °C for 2 hours. 2,2’-Dithiodiethanol (0.053 g, 0.342 mmol) was 
dissolved in CHCl3 (10 mL) and added to the mixture. The solution was 
refluxed at 40 °C for 60 hours. The reaction was diluted with CHCl3 (20 mL) 
and washed with water (10 mL), sat. NaHCO3 (10 mL), formic acid (0.1 M, 
10 mL), sat. brine (10 mL) and water (10 mL). The organic layer was dried 
on anhydrous MgSO4 and reduced under reduced pressure to give a red 
crude solid. This solid was purified using HPLC as described in HPLC 
Preparatory Method A, with the compound eluting at 11 minutes to give 
the title compound as a white solid.  
Mass Recovery: 
0.018 g, 5.3 % mass recovery 
m/z (ESI) 
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1003.3514 ([C48H58F2N6O10S2+Na]+ calculated mass 1003.3516, 0.2 ppm 
mean error)  
1H NMR: (400 MHz, CD3OD, δH (ppm)): 
8.42 (s, 2H, H-11, CH), 7.53 (d, 3JF-H = 13.3 Hz, 2H, H-3, CH), 7.14 (d, 4JF-H = 
7.3 Hz, 2H, H-17, CH), 4.55 (t, 3JH-H = 6.0 Hz, 4H, H-34, CH2), 3.66-3.64 (m, 
8H, H-21, H-23, piperazine, CH2) 3.47-3.41 (m, 2H, H-13  cyclopropane, 
CH), 3.20-3.18 (m, 8H, H-20, H-24 piperazine, CH2), 3.09 (t, 2JH-H = 6.0 Hz, 
4H, H-35, CH2), 1.50 (s, 18H, H-31, H-32, H-33, Boc group) ,1.27-1.22 (m, 
8H, cyclopropane, CH2) 
13C NMR: (100 MHz, CD3OD, δC (ppm)): 
172.5 (s, C-5), 163.8 (s, C-8), 154.6 (s, C-26), 152.9 (d, 1JF-C = 248.3 Hz), 
148.2 (s, C-11), 144.0 (d, 2JF-C = 10.5 Hz, C-18), 137.6 (s, C-7), 122.20 (d, 3JC-
F = 6.7 Hz, C-4), 112.3 (d, 2JF-C = 23.0 Hz, C-3), 108.8 (d, 4JF-C = 2.9 Hz, C-17), 
105.3 (s, C-16), 80.1 (s, C-30), 62.4 (s, C-34), 49.8 (s C-20, C-21, C-23 C-24), 
49.7 (s, C-20, C-21, C-23, C-24), 37.4 (s, C-35), 34.8 (s, C-13), 28.4 (s, C-31, 
C-32, C-33), 8.0 (s, C-14, C-15) 
19F NMR: (376 MHz, CD3OD, δF (ppm)): 
-123.60 - -123.55 (m, F-1) 
IR: (cm-1) 
2969 (C-H), 1731 (C=O, C-8, O-9) 1627 (C=O, C-5, O-6) 
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4.2.2.3 Disulfanediylbis(ethane-2,1-diyl) bis(1-cyclopropyl-6-fluoro-4-
oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylate) chloride, 66 
 
Chemical Formula: C38H46Cl2F2N6O6S2 
Molecular Weight: 855.84 
Compound 68 (0.018 g, 0.018 mmol) was dissolved in HCl (3 M, aq, 20 mL) 
and the solvent was removed under reduced pressure after 2 minutes to 
give the title compound as sticky yellow oil.  
Yield: 
0.015 g, 95.6% 
m/z (ESI) 
781.2662 ([C38H46F2N6O6S2+H]+ calculated mass 781.2648, 2.4 ppm mean 
error)  
1H NMR: (500 MHz, d6-DMSO, δH (ppm)): 
9.65 (s, broad, N-22), 8.38 (s, 2H, H-11, CH), 7.46 (d, 3JF-H = 13.2 Hz, 2H, H-
3, CH), 7.33 (d, 4JF-H = 7.3 Hz, 2H, H-17, CH), 4.41 (t, 3JH-H = 5.9 Hz, 4H, H-25, 
CH2), 3.59 (s, broad, 2H, H-13  cyclopropane, CH), 3.46 (s, 8H, H-21, H-23, 
piperazine, CH2) 3.29 (s, 8H, H-20, H-24 piperazine, CH2), 3.09 (t, 2JH-H = 
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6.0 Hz, 4H, H-26, CH2) ,1.24-1.23 (m, 4H, cyclopropane, CH2) 1.14 (s, 4H, 
cyclopropane, CH2) 
13C NMR: (125 MHz, d6-DMSO, δC (ppm)): 
171.3 (s, C-5), 163.2 (s, C-8), 152.0 (d, 1JF-C = 246.5 Hz), 148.2 (s, C-11), 
142.5 (d, 2JF-C = 10.1 Hz, C-18), 137.6 (s, C-7), 122.0 (d, 3JC-F = 6.9 Hz, C-4), 
111.3 (d, 2JF-C = 23.8 Hz, C-3), 108.2 (s, C-17), 106.4 (d, 4JF-C = 1.8 Hz, C-16), 
61.8 (s, C-25), 46.4 (s, C-20, C-21, C-23 C-24), 42.5 (s, C-20, C-21, C-23, C-
24), 36.7 (s, C-26), 34.9 (s, C-13), 7.4 (s, C-14, C-15) 
19F NMR: (376 MHz, d6-DMSO, δF (ppm)): 
-124.44 - -124.49 (m, F-1) 
IR: (cm-1) 
3353 (N-H), 1493 (C=O) 
 
 
 
 
 
 
 
 
 
 
 
 
130 
 
4.3 Biological Procedures 
 
4.3.1 Bacterial Strains 
 
The bacterial strain used for all studies was wild type E.coli BW25113. 
 
4.3.2 Media 
 
All solutions and media were prepared using MilliQ deionised H2O and 
sterilised by autoclave prior to use. LB media was prepared using 10 g 
tryptone, 5 g of yeast extract and 10 g NaCl per litre. 
 
4.3.3 Growth Assays 
 
OD650 Measurements 
Optical densities were recorded to 3 decimal places using a Biochrom 
Libra S11 Visible Spectrometer in plastic cuvettes with a 1 cm path length, 
and are accurate to ±0.0005. These values were used to normalise the 
OD650 of each culture prior to use in each growth assay. 
 
Plate Reader 
The plate reader used was an Epoch 2 Microplate Spectrophotometer. The 
OD650 was measured every 30 minutes for the specified time. The plate 
was shaken at 200 RPM between each measurement to maintain aerobic 
bacterial growth. Blank wells were measured for their optical densities 
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and subtracted from the sample wells to normalise the OD650 
measurements used for data analysis. 
 
Growth Assay 
Cultures of the BW25113 strain were inoculated into 5mL LB growth 
media and grown overnight at 37°C with shaking to promote aerobic 
growth. The OD650 was normalised to OD650 = 2. To a 96 well plate was 
added 200µl MilliQ deionised water in the external ring of wells, 196µl of 
LB and 4µl of DMSO in each of the blank wells and in each of the test wells 
191µl LB, 4µl of drug stock concentration and 5µl of normalised bacterial 
culture as shown in Table 9. The experiment was placed into the plate 
reader which ran as described above.   
 
 
Well Conc / 
µM 
Stock Conc / 
µM 
0 0 
2 10 
4 20 
6 30 
8 40 
10 50 
 
Table 9 General 96 well plate layout used for the growth assays 
 
 
 
1 2 3 4 5 6 7 8 9 10 11 12
A H2O H2O H2O H2O H2O H2O H2O H2O H2O H2O H2O H2O
B H2O Drug 1 Drug 1 Drug 1 Drug 2 Drug 2 Drug 2 Drug 3 Drug 3 Drug 3 Blank H2O
C H2O Drug 1 Drug 1 Drug 1 Drug 2 Drug 2 Drug 2 Drug 3 Drug 3 Drug 3 Blank H2O
D H2O Drug 1 Drug 1 Drug 1 Drug 2 Drug 2 Drug 2 Drug 3 Drug 3 Drug 3 Blank H2O
E H2O Drug 1 Drug 1 Drug 1 Drug 2 Drug 2 Drug 2 Drug 3 Drug 3 Drug 3 Variable H2O
F H2O Drug 1 Drug 1 Drug 1 Drug 2 Drug 2 Drug 2 Drug 3 Drug 3 Drug 3 Variable H2O
G H2O Drug 1 Drug 1 Drug 1 Drug 2 Drug 2 Drug 2 Drug 3 Drug 3 Drug 3 Variable H2O
H H2O H2O H2O H2O H2O H2O H2O H2O H2O H2O H2O H2O
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4.3.4 DNA Gyrase Assay 
 
Agarose Gel Electrophoresis 
The gel was run in TAE running buffer which was prepared using 750 mL of 
H2O, 48.4 g/L of Tris, 22.8 mL of glacial acetic acid, 200 mL of 29.2 g/L 
EDTA. The solution was made up to 1 L using H2O. The solution was 
diluted by 1 in 10 in H2O. The agarose gels used were prepared using 1% 
w/v agarose in 1 x TAE buffer. 
 
Stop Buffer 
Once the assay was completed, a combination of 24 : 1 solution of 
chloroform/isoamyl alcohol and stop buffer were used to stop the 
reaction. The stop buffer was prepared using 40% w/v sucrose, 12.11 g/L 
Tris·HCl (pH 7.5), 0.29 g/L EDTA and 0.5 mg/mL of bromophenol blue. 
 
DNA Gyrase Assay Buffer 
The assay buffer was used neat from the commercially available Inspiralis 
DNA Gyrase Assay Kit. The buffer contained 3.92 g/L Tris·HCl (pH 7.5), 1.79 
g/L KCl, 0.38 g/L MgCl2, 0.3 g/L dithiothreitol, 0.26 g/L spermidine, 0.5 g/L 
ATP, 6.5% (w/v) glycerol and 0.1 mg/mL BSA. 
 
DNA Gyrase Assay 
Stock solutions of 62 were created in DMSO. The antimicrobial 
compounds were combined with relaxed pBR322 DNA, DNA gyrase and 
assay buffer in H2O at fixed proportions. The solutions were incubated at 
37 °C for 30 minutes. The assay was stopped with the addition of 30 μL of 
24:1 CHCl3 : isoamyl alcohol and 30 μL stop buffer. A portion of 20 μL was 
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loaded into a 1% agarose gel. The gel was subjected to electrophoresis for 
90 minutes at 75 volts. The gel was stained using 0.01% SYBR SAFE in TAE 
buffer for 50 minutes and photographed using a gel doc. 
 
 Volumes added / µl 
 
Positive 
Control 
Negative 
Control 
Test 
Wells 
DMSO 
control 
H2O 21.5 23.5 20.5 20.5 
pBr322 0.5 0.5 0.5 0.5 
Assay Buffer 6 6 6 6 
Drug Stock 0 0 1 0 
DMSO 0 0 0 1 
Gyrase Aliquot 2 0 2 2 
 
Stock Drug Conc / 
µM 
Assay Drug Conc / 
µM 
0 0 
15 0.5 
30 1 
150 5 
300 10 
600 20 
 
 
Table 10 Volumes added to each well of the DNA Gyrase binding assay and the stock 
drug concentrations used 
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Abbreviations  
 
AAC   Antibiotic-Antibody Conjugate 
ATP   Adenylate TriPhosphate 
DNA    Deoxyribose Nucleic Acid 
DSB   Disulfide bond forming 
DTT   Dithiotreitol 
E. coli   Escherichia coli 
E. faecium  Enterococcus faecium 
GSSG   Glutathione Disulfide 
K. pneumoniae Klebsiella pneumoniae 
MATE   Multi Antibiotic and Toxin Extruders 
MIC   Minimum Inhibitory Concentration  
MRSA   Methicillin-resistant Staphylococcus aureus 
NER   Nucleotide Excision Repair 
PAF   Mycobacteria proteasome accessory factor 
PBP   Penicillin Binding Protein 
PEG   Polyethylene Glycol 
QRDR   Quinolone Resistance Determining Region 
ROS   Reactive Oxygen Species 
S. aureus  Staphylococcus aureus 
S. typhi   Staphylococcus typhi 
SOD   Superoxide dismutase 
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Chemistry Terms 
 
α   Alpha 
β   Beta 
Boc   tert-Butyloxycarbonyl 
CD3OD  Deuterated methanol 
CDCl3   Deuterated chloroform 
CHCl3   Chloroform 
Cip   Ciprofloxacin 
Conc   Concentration 
DCC   N,N’-Dicyclohexylcarbodiimide 
DCM   Dichloromethane 
DIPEA   N,N’-Diisopropylethylamine 
DMAP   4-Dimethylaminopyridine 
DMF  Dimethylformamide 
EDC   1-Ethyl-3-(3’-dimethylaminopropyl)carbodiimide 
EtOAc   Ethyl acetate 
FA  Formic Acid 
HATU 1-[Bis(dimethylamino)methylene]-1H-1,2,3-
triazolo[4,5b]pyridinium 3-oxid hexafluorophosphate 
HCl   Hydrochloric acid 
HOBt   N-Hydroxybenzotriazolee hydrate 
m.p.   Melting point 
MeOH   Methanol 
MgSO4  Magnesium Sulphate 
Na2CO3  Sodium Carbonate 
NaHCO3  Sodium Hydrogen Carbonate 
NaOH   Sodium Hydroxide 
T3P  Propyl phosphonic anhydride  
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NMR Nuclear Magnetic Resonance Terms 
 
rt   Room Temperature 
SOCl2  Thionyl Chloride 
TFA   Trifuoroacetic acid 
TLC   Thin Layer Chromatography 
oC   Degrees Centigrade 
μM   Micromolar 
cm-1   Wavenumber 
g  Grams 
g mol-1  Grams per mole 
hrs   Hours 
Hz   Hertz 
mM   millimolar 
M   Molar 
mol   Moles 
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Spectroscopy Terms 
 
1H   Proton 
13C  Carbon 
19F   Fluorine 
Calc   Calculated 
COSY   Correlation Spectroscopy 
δ   Chemical Shift 
d   Doublet 
ESI   Electronspray Ionisation 
M   Multiplet 
m/z   Mass to charge ratio 
ppm  Parts per million 
Rf   Retention factor 
s   Singlet 
t  Triplet  
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